WO2016073895A1 - Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders - Google Patents

Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders Download PDF

Info

Publication number
WO2016073895A1
WO2016073895A1 PCT/US2015/059541 US2015059541W WO2016073895A1 WO 2016073895 A1 WO2016073895 A1 WO 2016073895A1 US 2015059541 W US2015059541 W US 2015059541W WO 2016073895 A1 WO2016073895 A1 WO 2016073895A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
substituted
occurrences
membered
alkylene
Prior art date
Application number
PCT/US2015/059541
Other languages
English (en)
French (fr)
Inventor
Renato T. Skerlj
Peter T. Lansbury
Andrew C. Good
Elyse Marie Josée BOURQUE
Original Assignee
Lysosomal Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ731897A priority Critical patent/NZ731897B2/en
Priority to JP2017544549A priority patent/JP6734860B2/ja
Priority to FIEP15857508.4T priority patent/FI3215511T3/fi
Priority to DK15857508.4T priority patent/DK3215511T3/da
Priority to AU2015342887A priority patent/AU2015342887B2/en
Priority to EA201790995A priority patent/EA201790995A1/ru
Priority to CA2966583A priority patent/CA2966583A1/en
Application filed by Lysosomal Therapeutics Inc. filed Critical Lysosomal Therapeutics Inc.
Priority to CN201580068129.9A priority patent/CN107001379B/zh
Priority to IL252053A priority patent/IL252053B2/en
Priority to US15/523,769 priority patent/US10570135B2/en
Priority to KR1020177015300A priority patent/KR102662215B1/ko
Priority to EP15857508.4A priority patent/EP3215511B1/en
Priority to MX2017005940A priority patent/MX2017005940A/es
Priority to BR112017009276-0A priority patent/BR112017009276B1/pt
Priority to CN202211277924.7A priority patent/CN115925711A/zh
Publication of WO2016073895A1 publication Critical patent/WO2016073895A1/en
Priority to US15/440,107 priority patent/US9732089B2/en
Priority to US16/733,598 priority patent/US11091492B2/en
Priority to US17/369,507 priority patent/US11932645B2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the invention provides substituted pyrazolo[l,5-a]pyrimidines and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders in a patient.
  • Gaucher disease is a genetic disorder associated with a deficiency of the lysosomal enzyme, glucocerebrosidase. Gaucher disease has been reported to have an incidence of approximately 1 in 20,000 live births in the general population, and it is a common lysosomal storage disorder. Current treatments for patients suffering from this disease include enzyme replacement therapy, which tends to be expensive, analgesics for bone pain relief, and medical procedures such as blood and platelet transfusions, splenectomy, and joint replacement for patients who experience bone erosion. However, new treatment options are needed having improved efficacy across a broader range of patients and/or reduced adverse side effects.
  • Parkinson's disease and diffuse Lewy Body Disease are a degenerative disorder of the central nervous system associated with death of dopamine-containing cells in a region of the midbrain. Parkinson's disease afflicts millions of people, and the incidence of the disease increases with age. Treatment of Parkinson's disease frequently involves use of levodopa and dopamine agonists. However, these drugs can produce significant side effects such as hallucinations, insomnia, nausea, and constipation. Further, patients often develop tolerance to these drugs such that the drugs become ineffective at treating the symptoms of the disease, while sometimes also producing a movement disorder side effect called dyskinesia. Diffuse Lewy Body disease is a dementia that is sometimes confused with Alzheimer's disease.
  • the invention provides substituted pyrazolo[l,5-a]pyrimidines and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease,
  • Parkinson's disease Lewy body disease, dementia, multiple system atrophy, epilepsy, bipolar disorder, schizophrenia, an anxiety disorder, major depression, polycystic kidney disease, type 2 diabetes, open angle glaucoma, multiple sclerosis, and multiple myeloma, in a patient.
  • one aspect of the invention provides a family of substituted pyrazolo[l,5-a]pyrimidines and related organic compounds embraced by Formula I that may be used in the methods, compositions, and kits described herein, wherein Formula I is represented by:
  • Another aspect of the invention provides a pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a substituted pyrazolo[l,5-a]pyrimidine or related organic compound described herein, such as a compound of Formula I.
  • Another aspect of the invention provides a method of treating a disorder, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, multiple system atrophy, epilepsy, bipolar disorder, schizophrenia, an anxiety disorder, major depression, polycystic kidney disease, type 2 diabetes, open angle glaucoma, multiple sclerosis, and multiple myeloma, in a patient.
  • the method comprises administering to a patient in need thereof a therapeutically effective amount of a substituted pyrazolo[l,5-a]pyrimidine or related organic compound described herein, such as a compound of Formula I, to treat the disorder, e.g.,
  • Gaucher disease Parkinson's disease, Lewy body disease, dementia, multiple system atrophy, epilepsy, bipolar disorder, schizophrenia, an anxiety disorder, major depression, polycystic kidney disease, type 2 diabetes, open angle glaucoma, multiple sclerosis, or multiple myeloma.
  • the invention provides substituted pyrazolo[l,5-a]pyrimidine and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders in a patient.
  • the practice of the present invention employs, unless otherwise indicated, conventional techniques of organic chemistry, pharmacology, cell biology, and biochemistry. Such techniques are explained in the literature, such as in "Comprehensive Organic Synthesis” (B.M. Trost & I. Fleming, eds., 1991- 1992); “Current protocols in molecular biology” (F.M.
  • alkyl refers to a saturated straight or branched hydrocarbon, such as a straight or branched group of 1-12, 1-10, or 1-6 carbon atoms, referred to herein as Ci-Cioalkyl, and Ci-C 6 alkyl, respectively.
  • Exemplary alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, 2-methyl-l -propyl, 2-methyl-2- propyl, 2-methyl- 1 -butyl, 3 -methyl- 1 -butyl, 2-methyl-3 -butyl, 2,2-dimethyl-l -propyl, 2- methyl-l-pentyl, 3 -methyl- 1-pentyl, 4-methyl-l-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-l -butyl, 3,3 -dimethyl- 1 -butyl, 2-ethyl-l -butyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, etc.
  • alkylene refers to a diradical of an alkyl group.
  • An exemplary alkylene group is -CH 2 CH 2 -.
  • haloalkyl refers to an alkyl group that is substituted with at least one halogen.
  • halogen for example, -CH 2 F, -CHF 2 , -CF 3 , -CH 2 CF 3 , -CF 2 CF 3 , and the like.
  • heteroalkyl refers to an "alkyl” group in which at least one carbon atom has been replaced with an O or S atom.
  • the heteroalkyl may be, for example, an -O-Ci-Cioalkyl group, an -Ci-C 6 alkylene-0-Ci-C 6 alkyl group, or a C1-C6 alkylene-OH group.
  • the "heteroalkyl” may be 2-8 membered heteroalkyl, indicating that the heteroalkyl contains from 2 to 8 atoms selected from the group consisting of carbon, oxygen, nitrogen, and sulfur.
  • the heteroalkyl may be a 2-6 membered, 4-8 membered, or a 5-8 membered heteroalkyl group (which may contain for example 1 or 2 heteroatoms selected from the group oxygen and nitrogen).
  • the heteroalkyl is an "alkyl" group in which 1-3 carbon atoms have been replaced with oxygen atoms.
  • One type of heteroalkyl group is an "alkoxyl" group.
  • alkenyl refers to an unsaturated straight or branched hydrocarbon having at least one carbon-carbon double bond, such as a straight or branched group of 2-12, 2-10, or 2-6 carbon atoms, referred to herein as C 2 _Ci 2 alkenyl, C 2 _Cioalkenyl, and C 2 _C 6 alkenyl, respectively.
  • alkenyl groups include vinyl, allyl, butenyl, pentenyl, hexenyl, butadienyl, pentadienyl, hexadienyl, 2-ethylhexenyl, 2 -propy 1-2 -butenyl, 4- (2-methyl-3-butene)-pentenyl, and the like.
  • alkynyl refers to an unsaturated straight or branched hydrocarbon having at least one carbon-carbon triple bond, such as a straight or branched group of 2-12, 2-10, or 2-6 carbon atoms, referred to herein as C 2 _Ci 2 alkynyl, C 2 _Cioalkynyl, and C 2 _ C 6 alkynyl, respectively.
  • exemplary alkynyl groups include ethynyl, prop-l-yn-l-yl, and but-1- yn-l-yl.
  • cycloalkyl refers to a monovalent saturated cyclic, bicyclic, or bridged cyclic (e.g., adamantyl) hydrocarbon group of 3-12, 3-8, 4-8, or 4-6 carbons, referred to herein, e.g., as "C4_ 8 cycloalkyl,” derived from a cycloalkane.
  • exemplary cycloalkyl groups include, but are not limited to, cyclohexanes, cyclopentanes, cyclobutanes and cyclopropanes.
  • cycloalkyl groups are optionally substituted at one or more ring positions with, for example, alkanoyl, alkoxy, alkyl, haloalkyl, alkenyl, alkynyl, amido, amidino, amino, aryl, arylalkyl, azido, carbamate, carbonate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, imino, ketone, nitro, phosphate, phosphonato, phosphinato, sulfate, sulfide, sulfonamido, sulfonyl or thiocarbonyl. Cycloalkyl groups can be fused to other cycloalkyl, aryl, or heterocyclyl groups. In certain embodiments, the cycloalkyl group is not substituted, i.
  • cycloalkyle refers to a diradical of an cycloalkyl group.
  • An exemplary cycloalkylene group is
  • cycloalkenyl refers to a monovalent unsaturated cyclic, bicyclic, or bridged cyclic (e.g., adamantyl) hydrocarbon group of 3-12, 3-8, 4-8, or 4-6 carbons containing one carbon-carbon double bond, referred to herein, e.g., as "C4- 8 cycloalkenyl,” derived from a cycloalkane.
  • exemplary cycloalkenyl groups include, but are not limited to, cyclohexenes, cyclopentenes, and cyclobutenes.
  • cycloalkenyl groups are optionally substituted at one or more ring positions with, for example, alkanoyl, alkoxy, alkyl, alkenyl, alkynyl, amido, amidino, amino, aryl, arylalkyl, azido, carbamate, carbonate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, imino, ketone, nitro, phosphate, phosphonato, phosphinato, sulfate, sulfide, sulfonamido, sulfonyl or thiocarbonyl.
  • the cycloalkenyl group is not substituted, i.e., it is unsubstituted.
  • aryl is art-recognized and refers to a carbocyclic aromatic group.
  • aryl groups include phenyl, naphthyl, anthracenyl, and the like.
  • the term "aryl” includes polycyclic ring systems having two or more carbocyclic rings in which two or more carbons are common to two adjoining rings (the rings are "fused rings") wherein at least one of the rings is aromatic and, e.g., the other ring(s) may be cycloalkyls, cycloalkenyls,
  • the aromatic ring may be substituted at one or more ring positions with, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, carboxylic acid, - C(0)alkyl, -CC ⁇ alkyl, carbonyl, carboxyl, alkylthio, sulfonyl, sulfonamido, sulfonamide, ketone, aldehyde, ester, heterocyclyl, aryl or heteroaryl moieties, -CF 3 , -CN, or the like.
  • the aromatic ring is substituted at one or more ring positions with halogen, alkyl, hydroxyl, or alkoxyl. In certain other embodiments, the aromatic ring is not substituted, i.e., it is unsubstituted. In certain embodiments, the aryl group is a 6-10 membered ring structure.
  • aralkyl refers to an alkyl group substituted with an aryl group.
  • bicyclic carbocyclyl that is partially unsaturated refers to a bicyclic carbocyclic group containing at least one double bond between ring atoms and at least one ring in the bicyclic carbocyclic group is not aromatic.
  • Representative examples of a bicyclic carbocyclyl that is partially unsaturated include, for example:
  • ortho, meta and para are art-recognized and refer to 1,2-, 1,3- and 1,4- disubstituted benzenes, respectively.
  • 1,2-dimethylbenzene and ortho- dimethylbenzene are synonymous.
  • heterocyclyl and “heterocyclic group” are art-recognized and refer to saturated, partially unsaturated, or aromatic 3- to 10-membered ring structures, alternatively 3- to 7-membered rings, whose ring structures include one to four heteroatoms, such as nitrogen, oxygen, and sulfur.
  • the number of ring atoms in the heterocyclyl group can be specified using C x -Cx nomenclature where x is an integer specifying the number of ring atoms.
  • a C3-C 7 heterocyclyl group refers to a saturated or partially unsaturated 3- to 7-membered ring structure containing one to four heteroatoms, such as nitrogen, oxygen, and sulfur.
  • C3-C7 indicates that the heterocyclic ring contains a total of from 3 to 7 ring atoms, inclusive of any heteroatoms that occupy a ring atom position.
  • a Csheterocyclyl is aziridinyl.
  • Heterocycles may also be mono-, bi-, or other multi-cyclic ring systems including a spirocyclic ring system where at least one ring contains a ring heteroatom.
  • a heterocycle may be fused to one or more aryl, partially unsaturated, or saturated rings.
  • Heterocyclyl groups include, for example, biotinyl, chromenyl, dihydrofuryl, dihydroindolyl, dihydropyranyl, dihydrothienyl, dithiazolyl, homopiperidinyl, imidazolidinyl, isoquinolyl, isothiazolidinyl, isooxazolidinyl, morpholinyl, oxolanyl, oxazolidinyl, phenoxanthenyl, piperazinyl, piperidinyl, pyranyl, pyrazolidinyl, pyrazolinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolidin-2-onyl, pyrrolinyl, tetrahydrofuryl, tetrahydroisoquinolyl, tetrahydropyranyl, tetrahydroquinolyl, thiazolidinyl,
  • the heterocyclic ring is optionally substituted at one or more positions with substituents such as alkanoyl, alkoxy, alkyl, alkenyl, alkynyl, amido, amidino, amino, aryl, arylalkyl, azido, carbamate, carbonate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, imino, ketone, nitro, oxo, phosphate, phosphonato, phosphinato, sulfate, sulfide, sulfonamido, sulfonyl and thiocarbonyl.
  • the heterocyclyl group is not substituted, i.e., it is unsubstituted.
  • bicyclic heterocyclyl refers to a heterocyclyl group that contains two rings that are fused together.
  • Representative examples of a bicyclic heterocyclyl include, for example:
  • the bicyclic heterocyclyl is an carbocyclic ring fused to partially unsaturated heterocyclic ring, that together form a bicyclic ring structure having 8-10 ring atoms (e.g., where there are 1, 2, 3, or 4 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur).
  • heterocycloalkyl is art-recognized and refers to a saturated heterocyclyl group as defined above.
  • the "heterocycloalkyl” is a 3 - to 10- membered ring structures, alternatively a 3- to 7-membered rings, whose ring structures include one to four heteroatoms, such as nitrogen, oxygen, and sulfur.
  • heterocycloalkylene of a heterocycloalkyl group.
  • heterocycloalkylene group is heterocycloalkylene may contain, for example, 3-6 ring atom (i.e., a 3-6 membered heterocycloalkylene).
  • the heterocycloalkylene is a 3-6 membered heterocycloalkylene containing 1, 2, or 3 three heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur.
  • heteroaryl is art-recognized and refers to aromatic groups that include at least one ring heteroatom. In certain instances, a heteroaryl group contains 1, 2, 3, or 4 ring heteroatoms.
  • heteroaryl groups include pyrrolyl, furanyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, pyrazolyl, pyridinyl, pyrazinyl, pyridazinyl and pyrimidinyl, and the like.
  • the heteroaryl ring may be substituted at one or more ring positions with, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, carboxylic acid, -C(0)alkyl, -CC ⁇ alkyl, carbonyl, carboxyl, alkylthio, sulfonyl, sulfonamido, sulfonamide, ketone, aldehyde, ester, heterocyclyl, aryl or heteroaryl moieties, -CF 3 , -CN, or the like.
  • heteroaryl also includes polycyclic ring systems having two or more rings in which two or more carbons are common to two adjoining rings (the rings are "fused rings") wherein at least one of the rings is heteroaromatic, e.g., the other cyclic rings may be cycloalkyls, cycloalkenyls, cycloalkynyls, and/or aryls.
  • the heteroaryl ring is substituted at one or more ring positions with halogen, alkyl, hydroxyl, or alkoxyl.
  • the heteroaryl ring is not substituted, i.e., it is unsubstituted.
  • the heteroaryl group is a 5- to 10-membered ring structure, alternatively a 5- to 6-membered ring structure, whose ring structure includes 1, 2, 3, or 4 heteroatoms, such as nitrogen, oxygen, and sulfur.
  • heteroarylkyl refers to an alkyl group substituted with a heteroaryl group.
  • amine and “amino” are art-recognized and refer to both unsubstituted and substituted amines, e.g., a moiety represented by the general formula -N(R 50 )(R 51 ), wherein R 50 and R 51 each independently represent hydrogen, alkyl, cycloalkyl, heterocyclyl, alkenyl, aryl, aralkyl, or -(CH 2 ) m -R 61 ; or R 50 and R 51 , taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure; R 61 represents an aryl, a cycloalkyl, a cycloalkenyl, a heterocycle or a polycycle; and m is zero or an integer in the range of 1 to 8.
  • R 50 and R 51 each independently represent hydrogen, alkyl, alkenyl, or -(CH 2 ) m
  • alkoxyl or "alkoxy” are art-recognized and refer to an alkyl group, as defined above, having an oxygen radical attached thereto.
  • Representative alkoxyl groups include methoxy, ethoxy, propyloxy, tert-butoxy and the like.
  • An "ether” is two hydrocarbons covalently linked by an oxygen. Accordingly, the substituent of an alkyl that renders that alkyl an ether is or resembles an alkoxyl, such as may be represented by one of -O-alkyl, -O-alkenyl, -O-alkynyl, -0-(CH 2 ) m -R6i, where m and 3 ⁇ 4i are described above.
  • R gj R3 ⁇ 4 and Rj are each independently alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, ketone, nitro, sulfide, sulfonyl, or sulfonamide.
  • Exemplary carbamates include arylcarbamates and heteroaryl carbamates, e.g., wherein at least one of Rg R ⁇ and Rj are independently aryl or heteroaryl, such as phenyl and pyridinyl.
  • carbonyl refers to the radical -C(O)-.
  • carboxylate refers to the radical -C(0)NRR', where R and R' may be the same or different. R and R' may be independently alkyl, aryl, arylalkyl, cycloalkyl, formyl, haloalkyl, heteroaryl, or heterocyclyl.
  • carboxy refers to the radical -COOH or its corresponding salts, e.g. -COONa, etc.
  • R a , R b and R c are each independently alkoxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydrogen, hydroxyl, ketone, or nitro.
  • the amide can be attached to another group through the carbon, the nitrogen, R b , R c , or R a .
  • the amide also may be cyclic, for example R b and R c , R a and R b , or R a and R c may be joined to form a 3- to 12-membered ring, such as a 3- to 10-membered ring or a 5- to 6-membered ring.
  • alkanoyl refers to a radical -O-CO-alkyl.
  • a cyclopentane susbsituted with an oxo group is cyclopentanone.
  • sulfonamide or “sulfonamido” as used herein refers to a radical having the structure -N(R r )-S(0)2-R s - or -S(0)2-N(R r )R s , where R r , and R s can be, for example, hydrogen, alkyl, aryl, cycloalkyl, and heterocyclyl.
  • Exemplary sulfonamides include alkylsulfonamides (e.g., where R s is alkyl), arylsulfonamides (e.g., where R s is aryl), cycloalkyl sulfonamides (e.g., where R s is cycloalkyl), and heterocyclyl sulfonamides (e.g., where R s is heterocyclyl), etc.
  • sulfonyl refers to a radical having the structure R U S02-, where R u can be alkyl, aryl, cycloalkyl, and heterocyclyl, e.g., alkylsulfonyl.
  • alkylsulfonyl refers to an alkyl group attached to a sulfonyl group.
  • the compounds of the disclosure may contain one or more chiral centers and/or double bonds and, therefore, exist as stereoisomers, such as geometric isomers, enantiomers or diastereomers.
  • stereoisomers when used herein consist of all geometric isomers, enantiomers or diastereomers. These compounds may be designated by the symbols "R” or "S,” depending on the configuration of substituents around the stereogenic carbon atom.
  • Stereoisomers include enantiomers and diastereomers. Mixtures of enantiomers or
  • diastereomers may be designated "( ⁇ )" in nomenclature, but the skilled artisan will recognize that a structure may denote a chiral center implicitly. It is understood that graphical depictions of chemical structures, e.g., generic chemical structures, encompass all stereoisomeric forms of the specified compounds, unless indicated otherwise.
  • Individual stereoisomers of compounds of the present invention can be prepared synthetically from commercially available starting materials that contain asymmetric or stereogenic centers, or by preparation of racemic mixtures followed by resolution methods well known to those of ordinary skill in the art. These methods of resolution are exemplified by (1) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography and liberation of the optically pure product from the auxiliary, (2) salt formation employing an optically active resolving agent, or (3) direct separation of the mixture of optical enantiomers on chiral chromatographic columns.
  • Stereoisomeric mixtures can also be resolved into their component stereoisomers by well- known methods, such as chiral-phase gas chromatography, chiral-phase high performance liquid chromatography, crystallizing the compound as a chiral salt complex, or crystallizing the compound in a chiral solvent. Further, enantiomers can be separated using supercritical fluid chromatographic (SFC) techniques described in the literature. Still further, stereoisomers can be obtained from stereomerically-pure intermediates, reagents, and catalysts by well-known asymmetric synthetic methods.
  • SFC supercritical fluid chromatographic
  • Geometric isomers can also exist in the compounds of the present invention.
  • the symbol denotes a bond that may be a single, double or triple bond as described herein.
  • the present invention encompasses the various geometric isomers and mixtures thereof resulting from the arrangement of substituents around a carbon-carbon double bond or arrangement of substituents around a carbocyclic ring.
  • Substituents around a carbon-carbon double bond are designated as being in the "Z” or "is” configuration wherein the terms “Z” and “is” are used in accordance with IUPAC standards. Unless otherwise specified, structures depicting double bonds encompass both the "is " and "Z” isomers.
  • Substituents around a carbon-carbon double bond alternatively can be referred to as “cis” or “trans,” where “cis” represents substituents on the same side of the double bond and “trans” represents substituents on opposite sides of the double bond.
  • the arrangement of substituents around a carbocyclic ring are designated as “cis” or “trans.”
  • the term “cis” represents substituents on the same side of the plane of the ring and the term “trans” represents substituents on opposite sides of the plane of the ring.
  • Mixtures of compounds wherein the substituents are disposed on both the same and opposite sides of plane of the ring are designated "cis/trans.”
  • the invention also embraces isotopically labeled compounds of the invention which are identical to those recited herein, except that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as 2 H, 3 H, 13 C, 14 C, 15 N, 18 0, 17 0, 31 P, 32 P, 35 S, 18 F, and 36 C1, respectively.
  • Certain isotopically-labeled disclosed compounds are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., 3 H) and carbon-14 (i.e., 14 C) isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., 2 H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances.
  • Isotopically labeled compounds of the invention can generally be prepared by following procedures analogous to those disclosed in, e.g., the Examples herein by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.
  • the terms "subject” and “patient” refer to organisms to be treated by the methods of the present invention. Such organisms are preferably mammals (e.g., murines, simians, equines, bovines, porcines, canines, felines, and the like), and more preferably humans.
  • mammals e.g., murines, simians, equines, bovines, porcines, canines, felines, and the like
  • humans preferably humans.
  • the term "effective amount” refers to the amount of a compound (e.g., a compound of the present invention) sufficient to effect beneficial or desired results.
  • An effective amount can be administered in one or more administrations, applications or dosages and is not intended to be limited to a particular formulation or administration route.
  • the term “treating” includes any effect, e.g., lessening, reducing, modulating, ameliorating or eliminating, that results in the improvement of the condition, disease, disorder, and the like, or ameliorating a symptom thereof.
  • composition refers to the combination of an active agent with a carrier, inert or active, making the composition especially suitable for diagnostic or therapeutic use in vivo or ex vivo.
  • the term "pharmaceutically acceptable carrier” refers to any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, emulsions (e.g., such as an oil/water or water/oil emulsions), and various types of wetting agents.
  • the compositions also can include stabilizers and preservatives.
  • stabilizers and adjuvants see Martin, Remington's Pharmaceutical Sciences, 15th Ed., Mack Publ. Co., Easton, PA [1975].
  • the term "pharmaceutically acceptable salt” refers to any pharmaceutically acceptable salt (e.g., acid or base) of a compound of the present invention which, upon administration to a subject, is capable of providing a compound of this invention or an active metabolite or residue thereof.
  • salts of the compounds of the present invention may be derived from inorganic or organic acids and bases.
  • acids include, but are not limited to, hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salicylic, succinic, toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic, ethanesulfonic, formic, benzoic, malonic, naphthalene- 2-sulfonic, benzenesulfonic acid, and the like.
  • Other acids such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.
  • bases include, but are not limited to, alkali metal (e.g., sodium) hydroxides, alkaline earth metal (e.g., magnesium) hydroxides, ammonia, and compounds of formula NW , wherein W is C 1-4 alkyl, and the like.
  • alkali metal e.g., sodium
  • alkaline earth metal e.g., magnesium
  • W is C 1-4 alkyl
  • salts include, but are not limited to: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate,
  • salts include anions of the compounds of the present invention compounded with a suitable cation such as Na + , NH 4 + , and NW 4 + (wherein W is a C 1-4 alkyl group), and the like.
  • salts of the compounds of the present invention are provided.
  • salts of acids and bases that are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound.
  • HATU 0-(7-azabenzotriazol-l-yl)-N,N,N',N'- tetramethyluronium hexafluorophosphate
  • DIPEA diisopropylethylamine
  • DMF dimethylformamide
  • DCM methylene chloride
  • Boc tert-butoxycarbonyl
  • THF tetrahydrofuran
  • THF trifluoroacetic acid
  • NMM N-methylmorpholine
  • TEA triethylamine
  • Boc anhydride ((Boc ⁇ O); dimethylsulfoxide (DMSO); diisopropylethylamine (DIEA); N,N-Dimethylpyridin-4-amine (DMAP); flash column chromatography (FCC); and
  • compositions and kits are described as having, including, or comprising specific components, or where processes and methods are described as having, including, or comprising specific steps, it is contemplated that, additionally, there are compositions and kits of the present invention that consist essentially of, or consist of, the recited components, and that there are processes and methods according to the present invention that consist essentially of, or consist of, the recited processing steps.
  • compositions specifying a percentage are by weight unless otherwise specified. Further, if a variable is not accompanied by a definition, then the previous definition of the variable controls.
  • One aspect of the invention provides substituted pyrazolo[l,5-a]pyrimidines and related organic compounds.
  • the substituted pyrazolo[l,5-a]pyrimidines and related organic compounds are contemplated to be useful in the methods, compositions, and kits described herein.
  • the substituted pyrazolo[l,5-a]pyrimidine or related organic compound is a compound embraced by Formula I:
  • R 1 and R 2 each represent independently for each occurrence hydrogen, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxyl, -(C 1-4 alkylene)-(2-6 membered heteroalkyl), cyclopropyl, cyano, chloro, fluoro, or -N(H)(R 3 );
  • R 3 represents independently for each occurrence hydrogen or C 1-4 alkyl
  • R 4 represents independently for each occurrence hydrogen, C 1-4 alkyl, or -C(0)R 3 ;
  • X 1 is one of the following: (a) a carbonyl-containing linker selected from -0(0) ⁇ ( ⁇ )- ⁇ and -C(0)N(H)(Ci-6 where ⁇ is a bond to A 1 ; or
  • a 1 is a cyclic group selected from:
  • bicyclic heterocyclyl containing at least one ring nitrogen atom, wherein the bicyclic heterocyclyl is substituted by 0, 1, or 2 occurrences of Y ⁇ nd O, 1, 2, or 3 occurrences of Y 2 ;
  • Y 1 represents, independently for each occurrence, one of the following:
  • heterocyclyl -O-(6-10 membered aryl), or -0-(C2-6 alkynyl); or
  • Y 2 represents, independently for each occurrence, Ci_6 alkyl, C3-6 cycloalkyl, halogen,haloalkyl, hydroxyl, Ci- 6 alkoxyl, C2-4 alkynyl, cyano, azido, -N(R 3 )2, -(Ci_6 alkylene)-(5-6 membered heterocyclyl), -(C e alkylene)-C02R 3 , or Ci_6 haloalkyl-substituted C3-6 cycloalkyl;
  • n 1, 2, or 3;
  • R 1 and R 2 are Ci-4 alkoxyl, -(C 1-4 alkylene)-(2-6 membered heteroalkyl), cyclopropyl, cyano, chloro, fluoro, or -N(H)(R 3 ); and
  • Definitions of the variables in Formula I above encompass multiple chemical groups.
  • the application contemplates embodiments where, for example, i) the definition of a variable is a single chemical group selected from those chemical groups set forth above, ii) the definition is a collection of two or more of the chemical groups selected from those set forth above, and iii) the compound is defined by a combination of variables in which the variables are defined by (i) or (ii) , e.g., such as where R 1 is Ci-4 alkyl or cyclopropyl, X 1 is -C(0)N(H)- ⁇ , and A 1 is phenyl substituted by 4-8 membered heteroalkyl.
  • R 1 represents independently for each occurrence C 1-4 alkyl, C 1-4 alkoxyl, cyclopropyl, cyano, chloro, or fluoro. In certain embodiments, R 1 is methyl. In certain embodiments, the R 1 groups are located at the 5 and 7 positions of the pyrazolo[l,5-a]pyrimidinyl.
  • n is 2. In certain other embodiments, n is 1.
  • R 2 is hydrogen. In certain embodiments, R 2 is methyl or halogen. In certain embodiments, R 2 is methyl or halomethyl. In certain embodiments, R 2 is methyl or cyclopropyl.
  • R 3 and R 4 each represent independently for each occurrence hydrogen, methyl, or ethyl. In certain embodiments, R 3 is hydrogen. In certain embodiments, R 4 is hydrogen. [0068] In certain embodiments, X 1 is -0(0) ⁇ ( ⁇ )- ⁇ . [0069] In certain embodiments, any occurrence of Y 2 is independently C e alkyl, C3-6 cycloalkyl, halogen, or hydroxyl. In certain embodiments, any occurrence of Y 2 is independently C1-3 alkyl.
  • a 1 is phenyl substituted by (a) 0, 1, 2, or 3 occurrences of Y 2 and (b) one of the following:
  • a 1 is phenyl substituted by (a) 0, 1, 2, or 3 occurrences of Y 2 and (b) one of the following:
  • a 1 is phenyl substituted by (a) 0 or 1 occurrences of Y 2 and (b) a 4-8 membered heteroalkyl.
  • a 1 is phenyl substituted by -0-(C 1-7 alkyl).
  • a 1 is phenyl substituted by -0-(C 4-7 alkyl).
  • a 1 is phenyl substituted by -O-butyl, -O-pentyl, or -O-hexyl.
  • a 1 is phenyl substituted is -OCH2CH2OCH2CH2.
  • a 1 is phenyl substituted by (a) 0 or 1 occurrences of Y 2 and (b) a 2-6 membered heteroalkyl optionally substituted by a 5-10 membered heteroaryl.
  • a 1 is phenyl substituted by (a) 0 or 1 occurrences of Y 2 and (b) a 2-6 membered heteroalkyl substituted by a 5-6 membered heteroaryl (which may be, for example, pyridinyl, pyrimidinyl, pyrazinyl, isooxazolyl, isothiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, imidazolinyl, oxazolinyl, pyrazolinyl, or thiazolinyl, each of which is optionally substituted by one or two substituents independently selected from the group consisting of C e alkyl, C3-6 cycloalkyl, halogen, C e haloalkyl, Ci ⁇ hydroxyalkyl, hydroxyl, Ci- 6 alkoxyl, cyano, -N(R 4 )2, amide, and -CO2H).
  • a 1 is phenyl substituted by (a) 0 or 1 occurrences of Y 2 and (b) -C ⁇ C-(Ci_6 alkylene)-OR 4 . In certain embodiments, A 1 is phenyl substituted by (a) 0 or 1 occurrences of Y 2 and (b) -C ⁇ C-CH 2 -0-CH 3 . In certain embodiments, A 1 is phenyl substituted by -C ⁇ C-CH 2 -0-CH 3 .
  • a 1 is C3-7 cycloalkyl substituted once by Y 1 and 0-1 occurrences of Y 2 .
  • a 1 is C5-1 0 cycloalkyl that is substituted by 1 or 2 occurrences of Y 1 and 0, 1, 2, or 3 occurrences of Y 2 .
  • a 1 is a bicyclic heterocyclyl containing at least one ring nitrogen atom, wherein the bicyclic heterocyclyl is substituted by 0, 1, or 2 occurrences of Y 1 and 0, 1, 2, or 3 occurrences of Y 2 .
  • a 1 is 1,2,3,4-tetrahydronaphthalenyl substituted by 0, 1, 2, or 3 occurrences of Y 2 .
  • Y 1 is a 2-8 membered heteroalkyl optionally substituted by a 6-10 membered aryl or a 3-10 membered heterocyclyl. In certain embodiments, Y 1 is a 2-8 membered heteroalkyl substituted by a 6-10 membered aryl or a 3-10 membered heterocyclyl. In certain embodiments, Y 1 is a 2-8 membered heteroalkyl substituted by a 3-10 membered heterocyclyl. In certain embodiments, Y 1 is a 2-8 membered heteroalkyl substituted by a 5-6 membered heteroaryl, such as pyrrolyl, furanyl, or pyridinyl. In certain embodiments, Y 1 is a 2-8 membered heteroalkyl.
  • Y 1 is 2-8 membered heteroalkyl. In certain embodiments, Y 1 is -0-(Ci_7 alkyl). In certain embodiments, Y 1 is -O-butyl, -O-pentyl, or -O-hexyl. In certain embodiments, Y 1 is -(C1-3 alkylene)-0-(5-6 membered heteroaryl). In certain embodiments, Y 1 is - ⁇ 3 ⁇ 4-0-(5-6 membered heteroaryl).
  • Y 1 is -(3 ⁇ 4- 0-(5-6 membered heteroaryl), wherein the 5-6 membered heteroaryl is furanyl, pyrrolyl, thiophenyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, isooxazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, imidazolinyl, oxazolinyl, pyrazolinyl, thiazolinyl, or triazolinyl, each of which is substituted by one or two substituents independently selected from the group consisting of Ci_6 alkyl, C3-6 cycloalkyl, halogen, Ci_6 haloalkyl, Ci_6 hydroxyalkyl, hydroxyl, Ci_6 alkoxyl, cyano, -N(R)
  • Y 1 is a 3-10 membered heterocyclyl, 6-10 membered aryl, -0-(3-6 membered heterocyclyl), -O-(6-10 membered aryl), or -0-(C2-6 alkynyl).
  • Y 1 is a 3-10 membered heterocyclyl selected from the group consisting of a 5-6 membered heteroaryl and a 5-6 membered heterocycloalkyl.
  • Y 1 is 5- membered heteroaryl.
  • Y 1 is a 5-membered heteroaryl substituted by one or two substituents independently selected from the group consisting of Ci_6 alkyl, C3-7 cycloalkyl, halogen, Ci_6 haloalkyl, Ci_6 hydroxyalkyl, hydroxyl, Ci_6 alkoxyl, cyano, -N(R 4 )2, amide, and -CO2H.
  • Y 1 is a 5-membered heteroaryl substituted by one or two substituents independently selected from the group consisting of Ci_6 alkyl, C3-6 cycloalkyl, halogen, Ci_6 haloalkyl, hydroxyl, and Ci_6 alkoxyl.
  • Y 1 is furanyl, pyrrolyl, thiophenyl, imidazolyl, pyrazolyl, oxazolyl, or thiazolyl.
  • Y 1 is furanyl, pyrrolyl, thiophenyl, imidazolyl, pyrazolyl, oxazolyl, or thiazolyl, each of which is substituted by one or two substituents independently selected from the group consisting of Ci_6 alkyl, C3-6 cycloalkyl, halogen, Ci_6 haloalkyl, Ci_6 hydroxyalkyl, hydroxyl, Ci_6 alkoxyl, cyano, -N(R 4 )2, amide, and -CO2H.
  • Y 1 is pyridinyl, pyrimidinyl, pyrazinyl, isooxazolyl, isothiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, imidazolinyl, oxazolinyl, pyrazolinyl, thiazolinyl, or triazolinyl.
  • Y 1 is pyridinyl, pyrimidinyl, pyrazinyl, isooxazolyl, isothiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, imidazolinyl, oxazolinyl, pyrazolinyl, thiazolinyl, or triazolinyl, each of which is substituted by one or two substituents independently selected from the group consisting of Ci_6 alkyl, C3-6 cycloalkyl, halogen, Ci_6 haloalkyl, Ci_6 hydroxyalkyl, hydroxyl, Ci_6 alkoxyl, cyano, -N(R 4 )2, amide, and -CO2H.
  • Y 1 is C 2 - 6 alkynyl, -C ⁇ C-(C 1-6 alkylene)-OR 4 , -C ⁇ C-(C 1-6 alkylene)-N(R 3 )2, -(C 2-4 alkynylene)-(5-6 membered heteroaryl), or C2-6 alkenyl.
  • Y 1 is C2-6 alkynyl.
  • Y 1 is -C ⁇ CH.
  • Y 1 is -C ⁇ C-(Ci_6 alkylene)-OR 4 .
  • Y 1 is -C ⁇ C-(Ci_6 alkylene)-0-(Ci_2 alkyl).
  • Y 1 is -C ⁇ C-CH2-0-CH 3 .
  • the description above describes multiple embodiments relating to compounds of Formula I.
  • the patent application specifically contemplates all combinations of the embodiments.
  • the invention contemplates a compound of Formula I wherein X 1 is -0(0) ⁇ ( ⁇ )- ⁇ , A 1 is phenyl substituted by (a) 0, 1, 2, or 3 occurrences of Y 2 and (b) 4-8 membered heteroalkyl, and Y 1 is Ci_6 alkyl or halogen.
  • the compound is represented by Formula 1-1 :
  • R 1 and R 2 each represent independently for each occurrence hydrogen, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxyl, cyclopropyl, cyano, chloro, or fluoro;
  • R 3 represents independently for each occurrence hydrogen or C 1-4 alkyl
  • R 4 represents independently for each occurrence hydrogen, Ci -4 alkyl, or -C(0)R 3 ;
  • X 1 is one of the following:
  • a 1 is a cyclic group selected from:
  • Y 1 represents, independently for each occurrence, one of the following:
  • ⁇ 2-8 membered heteroalkyl optionally substituted by a 6-10 membered aryl or a
  • Y 2 represents, independently for each occurrence, Ci_6 alkyl, C3-6 cycloalkyl, halogen, Ci_ 6 haloalkyl, Ci ⁇ hydroxyalkyl, hydroxyl, Ci- 6 alkoxyl, C 2 _ 4 alkynyl, cyano, azido, -N(R 3 ) 2 , -(Ci_ 6 alkylene)-(5-6 membered heterocyclyl), -(Ci_6 alkylene)-C0 2 R 3 , or Ci_6
  • n 1, 2, or 3;
  • R 1 or R 2 is other than hydrogen when A 1 is phenyl substituted by heteroalkyl.
  • Definitions of the variables in Formula 1-1 above encompass multiple chemical groups.
  • the application contemplates embodiments where, for example, i) the definition of a variable is a single chemical group selected from those chemical groups set forth above, ii) the definition is a collection of two or more of the chemical groups selected from those set forth above, and iii) the compound is defined by a combination of variables in which the variables are defined by (i) or (ii) , e.g., such as where R 1 is Ci_ 4 alkyl or cyclopropyl, X 1 is -C(0)N(H)- ⁇ , and A 1 is phenyl substituted by 4-8 membered heteroalkyl.
  • R 1 represents independently for each occurrence Ci_ 4 alkyl, Ci_ 4 haloalkyl, Ci_ 4 alkoxyl, cyclopropyl, cyano, chloro, or fluoro.
  • R 1 is methyl.
  • the R 1 groups are located at the 5 and 7 positions of the pyrazolo[l,5-a]pyrimidinyl.
  • n is 2. In certain other embodiments, n is 1. [0089] In certain embodiments, R 2 is hydrogen. In certain embodiments, R 2 is methyl or halogen. In certain embodiments, R 2 is methyl or halomethyl. In certain embodiments, R 2 is methyl or cyclopropyl.
  • R 3 and R 4 each represent independently for each occurrence hydrogen, methyl, or ethyl. In certain embodiments, R 3 is hydrogen. In certain embodiments, R 4 is hydrogen.
  • X 1 is -0(0) ⁇ ( ⁇ )- ⁇ .
  • any occurrence of Y 2 is independently Ci_6 alkyl, C3-6 cycloalkyl, halogen, or hydroxyl. In certain embodiments, any occurrence of Y 2 is independently C1-3 alkyl.
  • a 1 is phenyl substituted by (a) 0, 1, 2, or 3 occurrences of Y 2 and (b) one of the following:
  • a 1 is phenyl substituted by (a) 0, 1, 2, or 3 occurrences of Y 2 and (b) one of the following:
  • a 1 is phenyl substituted by (a) 0 or 1 occurrences of Y 2 and (b) a 4-8 membered heteroalkyl.
  • a 1 is phenyl substituted by -0-(Ci_7 alkyl).
  • a 1 is phenyl substituted by -0-(C 4 _7 alkyl).
  • a 1 is phenyl substituted by -O-butyl, -O-pentyl, or -O-hexyl.
  • a 1 is phenyl substituted is -OCH2CH2OCH2CH2.
  • a 1 is phenyl substituted by (a) 0 or 1 occurrences of Y 2 and (b) a 2-6 membered heteroalkyl optionally substituted by a 5-10 membered heteroaryl.
  • a 1 is phenyl substituted by (a) 0 or 1 occurrences of Y 2 and (b) a 2-6 membered heteroalkyl substituted by a 5-6 membered heteroaryl (which may be, for example, pyridinyl, pyrimidinyl, pyrazinyl, isooxazolyl, isothiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, imidazolinyl, oxazolinyl, pyrazolinyl, or thiazolinyl, each of which is optionally substituted by one or two substituents independently selected from the group consisting of C e alkyl, C3-6 cycloalkyl, halogen, C e haloalkyl, Ci ⁇ hydroxyalkyl, hydroxyl, Ci- 6 alkoxyl, cyano, -N(R 4 )2, amide, and -CO2H).
  • a 1 is phenyl substituted by (a) 0 or 1 occurrences of Y 2 and (b) -C ⁇ C-(Ci_6 alkylene)-OR 4 .
  • a 1 is phenyl substituted by (a) 0 or 1 occurrences of Y 2 and (b) -C ⁇ C-CH2-0-CH3.
  • a 1 is phenyl substituted by -C ⁇ C-CH 2 -0-CH 3 .
  • a 1 is C3-7 cycloalkyl substituted once by Y 1 and 0-1 occurrences of Y 2 .
  • a 1 is a bicyclic heterocyclyl containing at least one ring nitrogen atom, wherein the bicyclic heterocyclyl is substituted by 0, 1, or 2 occurrences of Y 1 and 0, 1, 2, or 3 occurrences of Y 2 .
  • Y 1 is a 2-8 membered heteroalkyl optionally substituted by a 6-10 membered aryl or a 3-10 membered heterocyclyl. In certain embodiments, Y 1 is a 2-8 membered heteroalkyl substituted by a 6-10 membered aryl or a 3-10 membered heterocyclyl. In certain embodiments, Y 1 is a 2-8 membered heteroalkyl substituted by a 3-10 membered heterocyclyl. In certain embodiments, Y 1 is a 2-8 membered heteroalkyl substituted by a 5-6 membered heteroaryl, such as pyrrolyl, furanyl, or pyridinyl. In certain embodiments, Y 1 is a 2-8 membered heteroalkyl.
  • Y 1 is -0-(C 1-7 alkyl). In certain embodiments, Y 1 is -O- butyl, -O-pentyl, or -O-hexyl. In certain embodiments, Y 1 is -(C 1-3 alkylene)-0-(5-6 membered heteroaryl). In certain embodiments, Y 1 is -CH 2 -0-(5-6 membered heteroaryl).
  • Y 1 is -CH 2 -0-(5-6 membered heteroaryl), wherein the 5-6 membered heteroaryl is furanyl, pyrrolyl, thiophenyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, isooxazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, imidazolinyl, oxazolinyl, pyrazolinyl, thiazolinyl, or triazolinyl, each of which is substituted by one or two substituents independently selected from the group consisting of Ci- 6 alkyl, C3-6 cycloalkyl, halogen, Ci_6 haloalkyl, Ci ⁇ hydroxyalkyl, hydroxyl, Ci- 6 alkoxyl, cyano, -N(R 4 )
  • Y 1 is a 3-10 membered heterocyclyl, 6-10 membered aryl, -0-(3-6 membered heterocyclyl), -O-(6-10 membered aryl), or -0-(C2-6 alkynyl).
  • Y 1 is a 3-10 membered heterocyclyl selected from the group consisting of a 5-6 membered heteroaryl and a 5-6 membered heterocycloalkyl.
  • Y 1 is a 5- membered heteroaryl.
  • Y 1 is a 5-membered heteroaryl substituted by one or two substituents independently selected from the group consisting of Ci_6 alkyl, C3-7 cycloalkyl, halogen, Ci_6 haloalkyl, Ci ⁇ hydroxyalkyl, hydroxyl, Ci- 6 alkoxyl, cyano, -N(R 4 )2, amide, and -CO2H.
  • Y 1 is a 5-membered heteroaryl substituted by one or two substituents independently selected from the group consisting of Ci_6 alkyl, C3-6 cycloalkyl, halogen, Ci_6 haloalkyl, hydroxyl, and Ci_6 alkoxyl.
  • Y 1 is furanyl, pyrrolyl, thiophenyl, imidazolyl, pyrazolyl, oxazolyl, or thiazolyl.
  • Y 1 is furanyl, pyrrolyl, thiophenyl, imidazolyl, pyrazolyl, oxazolyl, or thiazolyl, each of which is substituted by one or two substituents independently selected from the group consisting of Ci_6 alkyl, C3-6 cycloalkyl, halogen, Ci_6 haloalkyl, Ci ⁇ hydroxyalkyl, hydroxyl, Ci_6 alkoxyl, cyano, -N(R 4 )2, amide, and -CO2H.
  • Y 1 is pyridinyl, pyrimidinyl, pyrazinyl, isooxazolyl, isothiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, imidazolinyl, oxazolinyl, pyrazolinyl, thiazolinyl, or triazolinyl.
  • Y 1 is pyridinyl, pyrimidinyl, pyrazinyl, isooxazolyl, isothiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, imidazolinyl, oxazolinyl, pyrazolinyl, thiazolinyl, or triazolinyl, each of which is substituted by one or two substituents independently selected from the group consisting of Ci_6 alkyl, C3-6 cycloalkyl, halogen, Ci_6 haloalkyl, Ci ⁇ hydroxyalkyl, hydroxyl, Ci_6 alkoxyl, cyano, -N(R 4 )2, amide, and -CO2H.
  • Y 1 is C 2 - 6 alkynyl, -C ⁇ C-(C 1-6 alkylene)-OR 4 , -C ⁇ C-(C 1-6 alkylene)-N(R 3 )2, -(C 2-4 alkynylene)-(5-6 membered heteroaryl), or C2-6 alkenyl.
  • Y 1 is C2-6 alkynyl.
  • Y 1 is -C ⁇ CH.
  • Y 1 is -C ⁇ C-CH 2 -0-CH 3 .
  • the description above describes multiple embodiments relating to compounds of Formula I- l .
  • the patent application specifically contemplates all combinations of the embodiments.
  • the invention contemplates a compound of Formula I- l wherein X 1 is -0(0) ⁇ ( ⁇ )- ⁇ , A 1 is phenyl substituted by (a) 0, 1, 2, or 3 occurrences of Y 2 and (b) 4-8 membered heteroalkyl, and Y 1 is Ci_6 alkyl or halogen.
  • the compound is a compound of Formula I-A:
  • R 1 is independently methyl, cyclopropyl, isopropyl, or -(C 1-4 alkylene)-(2-6 membered heteroalkyl);
  • R 2 is hydrogen
  • R 3 and R 4 each represent independently for each occurrence hydrogen or C 1-4 alkyl;
  • a 1 is one of the following:
  • Y 1 represents, independently for each occurrence, a 2-8 membered heteroalkyl
  • Y 2 represents, independently for each occurrence, Ci_6 alkyl, C3-6 cycloalkyl, halogen, Ci_ 6 haloalkyl, Ci ⁇ hydroxyalkyl, hydroxyl, Ci- 6 alkoxyl, cyano, azido, -N(R 3 ) 2 , -(C e alkylene)- (5-6 membered heterocyclyl), -(Ci_6 alkylene)-C02R 3 , or Ci ⁇ haloalkyl-substituted C3-6 cycloalkyl.
  • Definitions of the variables in Formula I-A above encompass multiple chemical groups.
  • the application contemplates embodiments where, for example, i) the definition of a variable is a single chemical group selected from those chemical groups set forth above, ii) the definition is a collection of two or more of the chemical groups selected from those set forth above, and iii) the compound is defined by a combination of variables in which the variables are defined by (i) or (ii).
  • any occurrence of Y 2 is independently C 1-3 alkyl, halogen, or C 1-3 haloalkyl.
  • a 1 is C 3-10 cycloalkyl that is substituted by 1 or 2 occurrences of Y ⁇ nd O, 1, 2, or 3 occurrences of Y 2 .
  • a 1 is 1,2,3,4- tetrahydronaphthalenyl substituted by 0, 1, 2, or 3 occurrences of Y 2 .
  • R 1 is methyl. In certain embodiments, R 1 is further selected from halogen and halomethyl, such that R 1 may be methyl, halogen, or halomethyl.
  • R 2 is further selected from halogen, such that R 2 may be hydrogen or halogen.
  • the compound is a compound of Formula I-Al :
  • R 1 is independently methyl, cyclopropyl, or isopropyl
  • R 2 is hydrogen
  • R 3 and R 4 each represent independently for each occurrence hydrogen or C 1-4 alkyl;
  • A is phenyl substituted by (a) 0, 1, 2, or 3 occurrences of Y 2 and (b) one of the following:
  • Y 2 represents, independently for each occurrence, Ci_6 alkyl, C3-6 cycloalkyl, halogen, Ci_ 6 haloalkyl, Ci ⁇ hydroxyalkyl, hydroxyl, Ci_6 alkoxyl, cyano, azido, -N(R 3 )2, -(Ci_6 alkylene)- (5-6 membered heterocyclyl), -(Ci_6 alkylene)-C02R 3 , or Ci ⁇ haloalkyl-substituted C3-6 cycloalkyl.
  • Definitions of the variables in Formula I-A above encompass multiple chemical groups.
  • the application contemplates embodiments where, for example, i) the definition of a variable is a single chemical group selected from those chemical groups set forth above, ii) the definition is a collection of two or more of the chemical groups selected from those set forth above, and iii) the compound is defined by a combination of variables in which the variables are defined by (i) or (ii), e.g., such as where R 1 is methyl, and A 1 is phenyl substituted by C 4 _8 alkoxyl.
  • any occurrence of Y 2 is independently C1-3 alkyl, halogen, or C1-3 haloalkyl.
  • a 1 is phenyl substituted by (a) 0 or 1 occurrences of Y 2 and (b) C4-8 alkoxyl. In certain embodiments, A 1 is phenyl substituted by -0-(C 4 -7 alkyl). In certain embodiments, A 1 is phenyl substituted by -0-(C 4 -7 alkyl) at the para-position of the phenyl group. In certain embodiments, A 1 is phenyl substituted by -O-butyl, -O-pentyl, or -O-hexyl.
  • a 1 is phenyl substituted by -O-butyl, -O-pentyl, or -O-hexyl at the para-position of the phenyl group. In certain embodiments, A 1 is phenyl substituted is
  • a 1 is phenyl substituted by (a) 0 or 1 occurrences of Y 2 and (b) a 2-4 membered heteroalkyl substituted by a 5-6 membered heteroaryl (which may be, for example, pyridinyl, pyrimidinyl, pyrazinyl, isooxazolyl, isothiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, imidazolinyl, oxazolinyl, pyrazolinyl, or thiazolinyl, each of which is optionally substituted by one or two substituents independently selected from the group consisting of Ci_6 alkyl, C3-6 cycloalkyl, halogen, Ci_6 haloalkyl, Ci_ 6 hydroxyalkyl, hydroxyl, Ci_6 alkoxyl, cyano, -N(R 4 )2, and amide).
  • a 5-6 membered heteroaryl
  • a 1 is phenyl substituted by (a) 0 or 1 occurrences of Y 2 and (b) -C ⁇ C-(Ci_6 alkylene)-OR 4 , where R 4 is C 1-4 alkyl.
  • a 1 is phenyl substituted by (a) 0 or 1 occurrences of Y 2 and (b) -C ⁇ C-CH 2 -0-CH 3 .
  • a 1 is phenyl substituted by -C ⁇ C-CH 2 -0-CH 3 .
  • R 1 is methyl. In certain embodiments, R 1 is further selected from halogen and halomethyl, such that R 1 may be methyl, halogen, or halomethyl.
  • R 2 is further selected from halogen, such that R 2 may be hydrogen or halogen.
  • the compound is a compound of Formula I-B:
  • a 1 is phenyl substituted by (a) 0 or 1 occurrences of Y 2 and (b) C 4 _ 8 alkoxyl or -C ⁇ C-
  • Y 2 represents, independently for each occurrence, Ci-6 alkyl, C3-6 cycloalkyl, halogen, or Ci-6 haloalkyl.
  • Definitions of the variables in Formula I-B above encompass multiple chemical groups.
  • the application contemplates embodiments where, for example, i) the definition of a variable is a single chemical group selected from those chemical groups set forth above, ii) the definition is a collection of two or more of the chemical groups selected from those set forth above, and iii) the compound is defined by a combination of variables in which the variables are defined by (i) or (ii).
  • Another aspect of the invention provides a compound of Formula II:
  • R 1 and R 2 each represent independently for each occurrence hydrogen, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxyl, cyclopropyl, cyano, chloro, or fluoro;
  • R 3 represents independently for each occurrence hydrogen or C 1-4 alkyl
  • R 4 represents independently for each occurrence hydrogen, C 1-4 alkyl, or -C(0)R 3 ;
  • X 1 is one of the following:
  • A is phenyl substituted by (a) 0, 1, 2, or 3 occurrences of Y 2 and (b) one of the following:
  • Y 2 represents, independently for each occurrence, Ci_6 alkyl, C3-6 cycloalkyl, halogen, Ci-6 haloalkyl, Ci ⁇ hydroxyalkyl, hydroxyl, Ci_6 alkoxyl, cyano, azido, -N(R 3 )2, -(C e alkylene) (5-6 membered heterocyclyl), -(Ci-6 alkylene)-C02R 3 , or Ci-6 haloalkyl-substituted C3-6 cycloalkyl; and n is 1, 2, or 3.
  • Definitions of the variables in Formula II above encompass multiple chemical groups.
  • the application contemplates embodiments where, for example, i) the definition of a variable is a single chemical group selected from those chemical groups set forth above, ii) the definition is a collection of two or more of the chemical groups selected from those set forth above, and iii) the compound is defined by a combination of variables in which the variables are defined by (i) or (ii), e.g., such as where R 1 is C 1-4 alkyl or cyclopropyl, X 1 is -0(0) ⁇ ( ⁇ )- ⁇ , and A 1 is phenyl substituted by phenyl.
  • R 1 represents independently for each occurrence hydrogen, C 1-4 alkyl, C 1-4 alkoxyl, cyclopropyl, cyano, chloro, or fluoro. In certain embodiments, R 1 is methyl. In certain embodiments, the R 1 groups are located at the 5 and 7 positions of the pyrazolo[l,5-a]pyrimidinyl.
  • n is 2. In certain other embodiments, n is 1.
  • R 2 is hydrogen. In certain embodiments, R 2 is methyl or halogen. In certain embodiments, R 2 is methyl or halomethyl. In certain embodiments, R 2 is methyl or cyclopropyl.
  • R 3 and R 4 each represent independently for each occurrence hydrogen, methyl, or ethyl. In certain embodiments, R 3 is hydrogen. In certain embodiments, R 4 is hydrogen. [00131] In certain embodiments, X 1 is -0(0) ⁇ ( ⁇ )- ⁇ .
  • any occurrence of Y 2 is independently C e alkyl, C3-6 cycloalkyl, halogen, Ci- 6 haloalkyl, or hydroxyl. In certain embodiments, any occurrence of Y 2 is independently C 1-3 alkyl.
  • R 1 and R 2 each represent independently for each occurrence hydrogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxyl, -(C1-4 alkylene)-(2-6 membered heteroalkyl), cyclopropyl, cyano, chloro, or fluoro;
  • R 3 represents independently for each occurrence hydrogen or C1-4 alkyl
  • R 4 represents independently for each occurrence hydrogen, C1-4 alkyl, or -C(0)R 3 ;
  • X 1 is one of the following:
  • a 1 is one of the following:
  • phenyl substituted by 0, 1, 2, or 3 occurrences of Y 2 o 4-pyridinyl substituted by 0, 1, 2, or 3 occurrences of Y 2 ;
  • Y 2 represents, independently for each occurrence, Ci_6 alkyl, C3-6 cycloalkyl, halogen, Ci-6 haloalkyl, Ci-6 hydroxyalkyl, hydroxyl, Ci-6 alkoxyl, cyano, azido, -N(R 3 )2, -(Ci-6 alkylene)- (5-6 membered heterocyclyl), -(Ci_6 alkylene)-C02R 3 , or Ci ⁇ haloalkyl-substituted C3-6 cycloalkyl; and
  • n 1, 2, or 3;
  • X 1 is optionally substituted halophenyl or -phenyl-methoxy, then X 1 is -C(0)N(H)(C 2 -6 branched alkylene)- ⁇
  • Definitions of the variables in Formula Ila above encompass multiple chemical groups.
  • the application contemplates embodiments where, for example, i) the definition of a variable is a single chemical group selected from those chemical groups set forth above, ii) the definition is a collection of two or more of the chemical groups selected from those set forth above, and iii) the compound is defined by a combination of variables in which the variables are defined by (i) or (ii), e.g., such as where R 1 is C 1-4 alkyl or cyclopropyl, X 1 is -0(0) ⁇ ( ⁇ )- ⁇ , and A 1 is phenyl substituted by phenyl.
  • R 1 represents independently for each occurrence C 1-4 alkyl, C 1-4 alkoxyl, cyclopropyl, cyano, chloro, or fluoro. In certain embodiments, R 1 is methyl.
  • n is 2.
  • R 1 groups are located at the 5 and 7 positions of the pyrazolo[l,5-a]pyrimidinyl.
  • X 1 is -0(0) ⁇ ( ⁇ )- ⁇ .
  • Another aspect of the invention provides a compound of Formula III:
  • R 1 and R 2 each represent independently for each occurrence hydrogen, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxyl, -(C 1-4 alkylene)-(2-6 membered heteroalkyl), cyclopropyl, cyano, chloro, or fluoro;
  • R 3 represents independently for each occurrence hydrogen or C 1-4 alkyl
  • R 4 represents independently for each occurrence hydrogen, C 1-4 alkyl, or -C(0)R 3 ;
  • X 1 is one of the following:
  • a 1 is a cyclic group selected from:
  • Y 1 represents, independently for each occurrence, one of the following:
  • ⁇ 2-8 membered heteroalkyl optionally substituted by a 6-10 membered aryl or a
  • Y 2 represents, independently for each occurrence, Ci_6 alkyl, C3-6 cycloalkyl, halogen, Ci-6 haloalkyl, Ci ⁇ hydroxyalkyl, hydroxyl, Ci_6 alkoxyl, cyano, azido, -N(R 3 )2, -(Ci_6 alkylene)- (5-6 membered heterocyclyl), -(Ci_6 alkylene)-C02R 3 , or Ci ⁇ haloalkyl-substituted C3-6 cycloalkyl; and
  • n 1, 2, or 3.
  • Definitions of the variables in Formula III above encompass multiple chemical groups.
  • the application contemplates embodiments where, for example, i) the definition of a variable is a single chemical group selected from those chemical groups set forth above, ii) the definition is a collection of two or more of the chemical groups selected from those set forth above, and iii) the compound is defined by a combination of variables in which the variables are defined by (i) or (ii) , e.g., such as where R 1 is Ci-4 alkyl or cyclopropyl, X 1 is -C(0)N(H)- ⁇ , and A 1 is phenyl substituted by a 5-membered heteroaryl.
  • R 1 represents independently for each occurrence Ci-4 alkyl, Ci-4 alkoxyl, cyclopropyl, cyano, chloro, or fluoro. In certain embodiments, R 1 is methyl. In certain embodiments, the R 1 groups are located at the 5 and 7 positions of the pyrazolo[l,5-a]pyrimidinyl.
  • n is 2. In certain other embodiments, n is 1.
  • R 2 is hydrogen. In certain embodiments, R 2 is methyl or halogen. In certain embodiments, R 2 is methyl or halomethyl. In certain embodiments, R 2 is methyl or cyclopropyl.
  • R 3 and R 4 each represent independently for each occurrence hydrogen, methyl, or ethyl. In certain embodiments, R 3 is hydrogen. In certain embodiments, R 4 is hydrogen.
  • X 1 is -0(0) ⁇ ( ⁇ )- ⁇ .
  • any occurrence of Y 2 is independently Ci_6 alkyl, C3-6 cycloalkyl, halogen, or hydroxyl. In certain embodiments, any occurrence of Y 2 is independently C1-3 alkyl.
  • a 1 is phenyl substituted by (a) 0, 1, 2, or 3 occurrences of Y 2 and (b) a 5-membered heteroaryl substituted by 0, 1, 2, or 3 occurrences of Y 2 .
  • a 1 is phenyl substituted by (a) Ci_6 alkyl or halogen and (b) a 5-membered heteroaryl selected from the group consisting of furanyl, thiophenyl, or oxazolyl.
  • a 1 is phenyl substituted by Ci-6 hydroxyalkyl.
  • a 1 is 5-6 membered heteroaryl substituted by 1 or 2 occurrences of Y 1 and a 5-membered heteroaryl selected from the group consisting of furanyl, thiophenyl, or oxazolyl.
  • a 1 is pyridinyl substituted by 1 or 2 occurrences of Y 1 and a 5-membered heteroaryl selected from the group consisting of furanyl, thiophenyl, or oxazolyl.
  • Y 1 is a 2-8 membered heteroalkyl optionally substituted by a 6-10 membered aryl or a 3-10 membered heterocyclyl. In certain embodiments, Y 1 is a 2-8 membered heteroalkyl substituted by a 6-10 membered aryl or a 3-10 membered heterocyclyl. In certain embodiments, Y 1 is a 2-8 membered heteroalkyl substituted by a 3-10 membered heterocyclyl. In certain embodiments, Y 1 is a 2-8 membered heteroalkyl substituted by a 5-6 membered heteroaryl, such as pyrrolyl, furanyl, or pyridinyl. In certain embodiments, Y 1 is a 2-8 membered heteroalkyl.
  • Y 1 is -0-(C 1-7 alkyl). In certain embodiments, Y 1 is -O- butyl, -O-pentyl, or -O-hexyl. In certain embodiments, Y 1 is -(C 1-3 alkylene)-0-(5-6 membered heteroaryl). In certain embodiments, Y 1 is -CH 2 -0-(5-6 membered heteroaryl).
  • Y 1 is -CH 2 -0-(5-6 membered heteroaryl), wherein the 5-6 membered heteroaryl is furanyl, pyrrolyl, thiophenyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, or pyridinyl, each of which is substituted by one or two substituents independently selected from the group consisting of Ci_ 6 alkyl, C 3 _6 cycloalkyl, halogen, haloalkyl, Ci ⁇ hydroxyalkyl, hydroxyl, Ci-6 alkoxyl, cyano, -N(R 4 )2, and amide.
  • Y 1 is a 3-10 membered heterocyclyl, 6-10 membered aryl, C 3 - 7 cycloalkyl, -0-(3-6 membered heterocyclyl), -O-(6-10 membered aryl), or -0-(C2-6 alkynyl).
  • Y 1 is a 3-10 membered heterocyclyl selected from the group consisting of a 5-6 membered heteroaryl and a 5-6 membered heterocycloalkyl.
  • Y 1 is 5-membered heteroaryl.
  • Y 1 is a 5-membered heteroaryl substituted by one or two substituents independently selected from the group consisting of Ci_6 alkyl, C 3 _6 cycloalkyl, halogen, Ci_6 haloalkyl, Ci_6 hydroxyalkyl, hydroxyl, Ci-6 alkoxyl, cyano, -N(R 4 ) 2 , and amide.
  • Y 1 is a 5-membered heteroaryl substituted by one or two substituents independently selected from the group consisting of Ci_6 alkyl, C 3 -6 cycloalkyl, halogen, Ci-6 haloalkyl, hydroxyl, and Ci-6 alkoxyl.
  • Y 1 is furanyl, pyrrolyl, thiophenyl, imidazolyl, pyrazolyl, oxazolyl, or thiazolyl.
  • Y 1 is furanyl, pyrrolyl, thiophenyl, imidazolyl, pyrazolyl, oxazolyl, or thiazolyl, each of which is substituted by one or two substituents independently selected from the group consisting of Ci_6 alkyl, C3-6 cycloalkyl, halogen, Ci_6 haloalkyl, Ci ⁇ hydroxyalkyl, hydroxyl, Ci- 6 alkoxyl, cyano, -N(R 4 )2, and amide.
  • Y 1 is pyridinyl, pyrimidinyl, pyrazinyl, isooxazolyl, isothiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, imidazolinyl, oxazolinyl, pyrazolinyl, or thiazolinyl.
  • Y 1 is pyridinyl, pyrimidinyl, pyrazinyl, isooxazolyl, isothiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, imidazolinyl, oxazolinyl, pyrazolinyl, or thiazolinyl, each of which is substituted by one or two substituents independently selected from the group consisting of C h alky!, C3-6 cycloalkyl, halogen, Ci_6 haloalkyl, Ci_6 hydroxyalkyl, hydroxyl, Ci_6 alkoxyl, cyano, -N(R 4 )2, and amide.
  • Y 1 is C 2 - 6 alkynyl, -C ⁇ C-(C 1-6 alkylene)-OR 4 , -OC-(C 1-6 alkylene)-N(R 3 )2, -(C 2-4 alkynylene)-(5-6 membered heteroaryl), or C2-6 alkenyl.
  • Y 1 is C2-6 alkynyl.
  • Y 1 is -C ⁇ CH.
  • Y 1 is -C ⁇ C-(Ci_6 alkylene)-OR 4 . In certain embodiments, Y 1 is -C ⁇ C-(Ci_6 alkylene)-0-(Ci_2 alkyl). In certain embodiments, Y 1 is -C ⁇ C-CH2-0-CH 3 .
  • the description above describes multiple embodiments relating to compounds of Formula III.
  • the patent application specifically contemplates all combinations of the embodiments.
  • the invention contemplates a compound of Formula III wherein R 1 is methyl, X 1 is -0(0) ⁇ ( ⁇ )- ⁇ , A 1 is phenyl substituted by (a) 0, 1, 2, or 3 occurrences of Y 2 and (b) a 5 -membered heteroaryl.
  • the compound is a compound of Formula III-A:
  • R 1 is independently methyl, cyclopropyl, or isopropyl
  • R 2 is hydrogen
  • a 1 is phenyl substituted by (a) Ci_6 alkyl or halogen and (b) a 5-membered heteroaryl selected from the group consisting of furanyl, thiophenyl, or oxazolyl C 4 _8 alkoxyl, each of which is optionally substituted by 1 or substituents independently selected from the group consisting of alkyl, halogen, and haloalkyl.
  • Definitions of the variables in Formula III-A above encompass multiple chemical groups.
  • the application contemplates embodiments where, for example, i) the definition of a variable is a single chemical group selected from those chemical groups set forth above, ii) the definition is a collection of two or more of the chemical groups selected from those set forth above, and iii) the compound is defined by a combination of variables in which the variables are defined by (i) or (ii).
  • the compound is one of the compounds listed in Table 1 or 2 below or a pharmaceutically acceptable salt thereof.
  • the synthetic route illustrated in Scheme 2 depicts an exemplary procedure for preparing substituted pyrazolo[l,5-a]pyrimidine compounds.
  • coupling of carboxylic acid C with a variety of substituted aromatic or heteraromatic amines may be accomplished using standard peptide coupling procedures, such as HATU and/or HOBT in DMF in the presence of DIPEA.
  • carboxylic ester B may be treated with AlMe 3 to afford the intermediate Weinreb amide, which after reaction with an amine provides substituted amide D.
  • the reaction is performed in a stepwise manner where a bromo or iodo-substituted aromatic or heteraromatic amine is coupled with the Weinreb amide to form the iodo or bromo-substituted amide E.
  • the bromo or iodo moiety may be used to couple a variety of functional groups using standard coupling procedures, such as acetylenes using Sonogashira coupling, boronic acids using Suzuki coupling, and amines using Buchwald coupling to produce substituted amide D.
  • reaction procedures in Scheme 2 are contemplated to be amenable to preparing a wide variety of substituted pyrazolo[l,5-a]pyrimidine carboxamide compounds having different substituents at the A 1 and Y 1 positions.
  • a functional group that is part of the A 1 and/or Y 1 would not be amenable to a reaction condition described in Scheme 2, it is contemplated that the functional group can first be protected using standard protecting group chemistry and strategies, and then the protecting group is removed after completing the desired synthetic transformation. See, for example, Greene, T.W.; Wuts, P.G.M.
  • a functional group in substituent A 1 and Y 1 can converted to another functional group using standard functional group manipulation procedures known in the art. See, for example, "Comprehensive Organic Synthesis” (B.M. Trost & I. Fleming, eds., 1991-1992).
  • the invention provides methods of treating medical disorders, such as Gaucher disease, Parkinson's disease, Lewy body disease, dementia, multiple system atrophy, epilepsy, bipolar disorder, schizophrenia, an anxiety disorder, major depression, polycystic kidney disease, type 2 diabetes, open angle glaucoma, multiple sclerosis, and multiple myeloma, using the substituted pyrazolo[l,5-a]pyrimidine, related compounds, and pharmaceutical
  • compositions described herein Treatment methods include the use of substituted pyrazolo[l,5- ajpyrimidine or related organic compounds described herein as stand-alone therapeutic agents and/or as part of a combination therapy with another therapeutic agent.
  • substituted pyrazolo[l,5-a]pyrimidines and related organic compounds described herein may activate glucocerebrosidase (Gcase).
  • One aspect of the invention provides a method of treating disorder selected from the group consisting of Gaucher disease, Parkinson's disease, Lewy body disease, dementia, multiple system atrophy, epilepsy, bipolar disorder, schizophrenia, an anxiety disorder, major depression, polycystic kidney disease, type 2 diabetes, open angle glaucoma, multiple sclerosis, and multiple myeloma.
  • the method comprises administering to a patient in need thereof a therapeutically effective amount of a substituted pyrazolo[l,5-a]pyrimidine or related organic compound described herein to treat the disorder.
  • the compound may be a compound of Formula I, which, as described above in Section II, is represented by:
  • R 1 and R 2 each represent independently for each occurrence hydrogen, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxyl, -(C 1-4 alkylene)-(2-6 membered heteroalkyl), cyclopropyl, cyano, chloro, fluoro, or -N(H)(R 3 );
  • R 3 represents independently for each occurrence hydrogen or C 1-4 alkyl
  • R 4 represents independently for each occurrence hydrogen, Ci-4 alkyl, or -C(0)R 3
  • X 1 is one of the following:
  • a 1 is a cyclic group selected from:
  • bicyclic heterocyclyl containing at least one ring nitrogen atom, wherein the bicyclic heterocyclyl is substituted by 0, 1, or 2 occurrences of Y ⁇ nd O, 1, 2, or 3 occurrences of Y 2 ;
  • Y 1 represents, independently for each occurrence, one of the following:
  • heterocyclyl -O-(6-10 membered aryl), or -0-(C 2 -6 alkynyl); or
  • Ci_6 alkyl C3-6 cycloalkyl, halogen, Ci_ 6 haloalkyl, Ci ⁇ hydroxyalkyl, hydroxyl, Ci- 6 alkoxyl, C2-4 alkynyl, cyano, azido, -N(R 3 )2, -(Ci-6 alkylene)-(5-6 membered heterocyclyl), -(C e alkylene)-C02R 3 , or Ci-6
  • n 1, 2, or 3;
  • R 1 and R 2 are Ci-4 alkoxyl, -(C 1-4 alkylene)-(2-6 membered heteroalkyl), cyclopropyl, cyano, chloro, fluoro, or -N(H)(R 3 ); and
  • the compound is a compound of Formula II. In certain embodiments, the compound is a compound of Formula III.
  • the disorder is Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy. In certain embodiments, the disorder is Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy. In certain other embodiments, the disorder is Gaucher disease. In certain
  • the disorder is Parkinson's disease. In certain embodiments, the disorder is
  • the disorder is dementia. In certain embodiments, the disorder is a dementia selected from the group consisting of Alzheimer's disease, frontotemporal dementia, and a Lewy body variant of Alzheimer's disease. In certain embodiments, the disorder is multiple system atrophy.
  • the disorder is an anxiety disorder, such as panic disorder, social anxiety disorder, or generalized anxiety disorder.
  • Efficacy of the compounds in treating Gaucher disease, Parkinson's disease, Lewy body disease, dementia, multiple system atrophy, epilepsy, bipolar disorder, schizophrenia, an anxiety disorder, major depression, polycystic kidney disease, type 2 diabetes, open angle glaucoma, multiple sclerosis, and multiple myeloma may be evaluated by testing the compounds in assays known in the art for evaluating efficacy against these diseases and/or, e.g., for activation of glucocerebrosidase (Gcase), as discussed in the Examples below.
  • Gcase glucocerebrosidase
  • the patient is a human.
  • the compound is one of the generic or specific compounds described in Section II, such as a compound of Formula I, a compound embraced by one of the further embodiments describing definitions for certain variables of Formula I, a compound of Formula I-A, or a compound embraced by one of the further embodiments describing definitions for certain variables of Formula I-A.
  • the compound is a compound of Formula II or III or a compound embraced by one of the further embodiments describing definitions for certain variables of Formula II or III.
  • Another aspect of the invention relates to compounds and compositions described herein for use in treating a disorder described herein. Another aspect of the invention pertains to use of a compound or composition described herein in the preparation of a medicament for treating a disorder described herein.
  • the invention embraces combination therapy, which includes the administration of a substituted pyrazolo[l,5-a]pyrimidine or related compound described herein (such as compound of Formula I, I-A, II, or III) and a second agent as part of a specific treatment regimen intended to provide the beneficial effect from the co-action of these therapeutic agents.
  • the beneficial effect of the combination may include pharmacokinetic or pharmacodynamic co-action resulting from the combination of therapeutic agents.
  • Exemplary second agents for use in treating Gaucher disease include, for example, taliglucerase alfa, velaglucerase alfa, eliglustat, and miglustat.
  • Exemplary second agents for use in treating Parkinson's disease include, for example, levodopa, pramipexole, ropinirole, rotigotine, and apomorphine.
  • the invention provides pharmaceutical compositions comprising a substituted pyrazolo[l,5-a]pyrimidine or related organic compound described herein, such as a compound of Formula I, I-A, II, or III.
  • the pharmaceutical compositions preferably comprise a therapeutically-effective amount of one or more of the substituted pyrazolo[l,5-a]pyrimidine or related organic compounds described above, formulated together with one or more pharmaceutically acceptable carriers (additives) and/or diluents.
  • compositions of the present invention may be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets (e.g., those targeted for buccal, sublingual, and/or systemic absorption), boluses, powders, granules, pastes for application to the tongue; (2) parenteral administration by, for example, subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation; (3) topical application, for example, as a cream, ointment, or a controlled-release patch or spray applied to the skin; (4) intravaginally or intrarectally, for example, as a pessary, cream or foam; (5) sublingually; (6) ocularly; (7) transdermally; or (8) nasally.
  • oral administration for example, drenches (aqueous or non-aqueous solutions or suspensions),
  • terapéuticaally-effective amount means that amount of a compound, material, or composition comprising a compound of the present invention which is effective for producing some desired therapeutic effect in at least a sub-population of cells in an animal at a reasonable benefit/risk ratio applicable to any medical treatment.
  • phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
  • antioxidants examples include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
  • water soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like
  • oil-soluble antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), le
  • Formulations of the present invention include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal and/or parenteral administration.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.
  • the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration.
  • the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred per cent, this amount will range from about 0.1 per cent to about ninety-nine percent of active ingredient, preferably from about 5 percent to about 70 percent, most preferably from about 10 percent to about 30 percent.
  • a formulation of the present invention comprises an excipient selected from the group consisting of cyclodextrins, celluloses, liposomes, micelle forming agents, e.g., bile acids, and polymeric carriers, e.g., polyesters and polyanhydrides; and a compound of the present invention.
  • an aforementioned formulation renders orally bioavailable a compound of the present invention.
  • Methods of preparing these formulations or compositions include the step of bringing into association a compound of the present invention with the carrier and, optionally, one or more accessory ingredients.
  • the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
  • Formulations of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present invention as an active ingredient.
  • a compound of the present invention may also be administered as a bolus, electuary or paste.
  • the active ingredient is mixed with one or more pharmaceutically-acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds and surfactants, such
  • compositions may also comprise buffering agents.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-shelled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
  • a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface- active or dispersing agent.
  • Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • the tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. They may be formulated for rapid release, e.g., freeze-dried.
  • compositions may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
  • These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner.
  • embedding compositions which can be used include polymeric substances and waxes.
  • the active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
  • Liquid dosage forms for oral administration of the compounds of the invention include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and
  • the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
  • adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
  • Suspensions in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
  • suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
  • Formulations of the pharmaceutical compositions of the invention for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more compounds of the invention with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
  • suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
  • Formulations of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.
  • Dosage forms for the topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants.
  • the active compound may be mixed under sterile conditions with a
  • pharmaceutically-acceptable carrier and with any preservatives, buffers, or propellants which may be required.
  • the ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • Powders and sprays can contain, in addition to a compound of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
  • Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
  • Transdermal patches have the added advantage of providing controlled delivery of a compound of the present invention to the body.
  • dosage forms can be made by dissolving or dispersing the compound in the proper medium.
  • Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the compound in a polymer matrix or gel.
  • Ophthalmic formulations, eye ointments, powders, solutions and the like, are also contemplated as being within the scope of this invention.
  • compositions of this invention suitable for parenteral administration comprise one or more compounds of the invention in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain sugars, alcohols, antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
  • aqueous and nonaqueous carriers examples include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate.
  • polyols such as glycerol, propylene glycol, polyethylene glycol, and the like
  • vegetable oils such as olive oil
  • injectable organic esters such as ethyl oleate.
  • Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
  • compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms upon the subject compounds may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.
  • adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents.
  • Injectable depot forms are made by forming microencapsule matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissue.
  • the compounds of the present invention are administered as pharmaceuticals, to humans and animals, they can be given per se or as a pharmaceutical composition containing, for example, 0.1 to 99% (more preferably, 10 to 30%) of active ingredient in combination with a pharmaceutically acceptable carrier.
  • the preparations of the present invention may be given orally, parenterally, topically, or rectally. They are of course given in forms suitable for each administration route. For example, they are administered in tablets or capsule form, by injection, inhalation, eye lotion, ointment, suppository, etc. administration by injection, infusion or inhalation; topical by lotion or ointment; and rectal by suppositories. Oral administrations are preferred.
  • parenteral administration and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal,
  • systemic administration means the administration of a compound, drug or other material other than directly into the central nervous system, such that it enters the patient's system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.
  • these compounds may be administered to humans and other animals for therapy by any suitable route of administration, including orally, nasally, as by, for example, a spray, rectally, intravaginally, parenterally, intracistemally and topically, as by powders, ointments or drops, including buccally and sublingually.
  • routes of administration including orally, nasally, as by, for example, a spray, rectally, intravaginally, parenterally, intracistemally and topically, as by powders, ointments or drops, including buccally and sublingually.
  • the compounds of the present invention which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically-acceptable dosage forms by conventional methods known to those of skill in the art.
  • Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
  • the selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion or metabolism of the particular compound being employed, the rate and extent of absorption, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
  • a physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required.
  • the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
  • a suitable daily dose of a compound of the invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above.
  • the compounds are administered at about 0.01 mg/kg to about 200 mg/kg, more preferably at about 0.1 mg/kg to about 100 mg/kg, even more preferably at about 0.5 mg/kg to about 50 mg/kg.
  • the effective amount may be less than when the agent is used alone.
  • the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. Preferred dosing is one administration per day. V. KITS FOR USE IN MEDICAL APPLICATIONS
  • kits for treating a disorder comprises: i) instructions for treating a medical disorder, such as Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy; and ii) a substituted pyrazolo[l,5-a]pyrimidine or related organic compound described herein, such as a compound of Formula I, I-A, II, or III.
  • a medical disorder such as Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy
  • a substituted pyrazolo[l,5-a]pyrimidine or related organic compound described herein such as a compound of Formula I, I-A, II, or III.
  • the kit may comprise one or more unit dosage forms containing an amount of a substituted pyrazolo[l,5-a]pyrimidine or related organic compound described herein, such as a compound of Formula I, that is effective for treating said medical disorder, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy.
  • a substituted pyrazolo[l,5-a]pyrimidine or related organic compound described herein such as a compound of Formula I, that is effective for treating said medical disorder, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy.
  • the invention contemplates a kit for treating Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, the kit comprising instructions for treating Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy and ii) a substituted pyrazolo[l,5-a]pyrimidine or related organic compound described herein, such as a compound of Formula I-A.
  • the reaction mixture was concentrated in vacuo, diluted with water (20 mL), extracted with ethyl acetate (3 X 15 mL), dried over a 2 S0 4 and concentrated in vacuo.
  • the crude compound was purified by FCC (eluent, 15-20% ethyl acetate in hexane) to afford tert-butyl (4-ethynylcyclohexyl)carbamate as a colorless oil (133 mg, 68%).
  • reaction mixture was filtered through a pad of celite and washed with ethyl acetate (10 mL). The filtrate was washed with ice water (lOmL) and brine (10 mL) and concentrated under vacuum to obtain crude compound which was purified by trituration in methanol to afford the title compound as an off-white solid (30 mg, 20%).
  • reaction mixture was diluted with water (5 mL), extracted with ethyl acetate (3 X 10 mL), dried over Na 2 S0 4 and concentrated in vacuo to provide crude compound, which was purified by FCC (eluent, 0-3% methanol in DCM) to afford N-(4-(3-hydroxyprop-l- yn-l-yl)phenyl)-5,7-dimethylpyrazolo[l,5-a]pyrimidine-3-carboxamide as an off-white solid (60 mg, 37%).
  • FCC eluent, 0-3% methanol in DCM
  • reaction mixture was diluted with water (10 mL), extracted with ethyl acetate (3 X 10 mL) and the combined organic layer was dried over sodium sulphate and concentrated in vacuo to obtain crude compound.
  • the crude compound was purified by FCC (eluent, 1-3% methanol in DCM) to afford the title compound as a white solid (40 mg, 12%).
  • reaction mixture was filtered through a pad of celite and washed with ethyl acetate (3 X 10 mL). The combined filtrate was washed with water, dried over sodium sulphate and concentrated in vacuo to obtain crude compound which was purified by FCC (eluent, 1-2% methanol in DCM) to afford the title compound as a white solid (160 mg, 47%).
  • reaction mixture was diluted with water (10 mL), extracted with ethyl acetate (3 X 10 mL), dried over Na 2 S0 4 and concentrated in vacuo to provide a crude compound which was then purified by FCC (eluent, 1-3% methanol in DCM) and triturated with methanol to afford the title compound as an off-white solid (58 mg, 16%).
  • reaction mixture was quenched with water (2 mL), extracted with ethyl acetate (3 X 10 mL), dried over Na 2 S0 4 and concentrated in vacuo to provide a crude product that was then purified by FCC (eluent, 5% methanol in DCM) to afford N-(4-hydroxyphenyl)-5,7-dimethylpyrazolo[l,5-a]pyrimidine-3-carboxamide as an off-white solid (284 mg, 64%).
  • FCC eluent, 5% methanol in DCM
  • reaction mixture was diluted with water (2 mL), extracted with ethyl acetate (3 X 10 mL), dried over a 2 S0 4 and concentrated in vacuo to provide a crude compound that was then purified by PREP HPLC (Column: YMC triart; Dimensions: (20 X 250mm X 5 ⁇ size); Method: Mobile phase A - 5mM Ammonium formate in water + 0.1% ammonia, Mobile phase B - Acetonitrile + 0.1% ammonia; Gradient programme: 10% B to 50% B) to afford the title compound as a white solid (34 mg, 61%).
  • reaction mixture was diluted with water (2 mL), extracted with ethyl acetate (3 X 10 mL), dried over sodium sulphate and concentrated in vacuo to provide a crude compound that was then purified by SFC purification (Column: Silica 2-ethyl pyridine; Dimensions: 30 X 250mm, 5 ⁇ size; Method: Mobile phase A - CO 2 , Mobile phase B - 5mM Ammonium formate in MeOH; Gradient Programme: 10% co-solvent to 50% maximum) to afford the title compound as a brown solid (24 mg, 62%).
  • reaction mixture was filtered through a pad of celite and washed with ethyl acetate (10 mL). The filtrate was washed with ice cooled water (lOmL) and brine (10 mL) and concentrated in vacuo to provide a crude compound that was then purified by FCC (eluent, 5-10% methanol in DCM) to afford the title compound as a brown solid (40 mg, 45%).
  • the reaction mixture was filtered through a pad of celite and washed with ethyl acetate (10 mL). The filtrate was washed with ice cooled water (lOmL) and brine (10 mL) and concentrated in vacuo to provide a crude compound.
  • the crude compound was purified by FCC (eluent, 5- 10% methanol in DCM) to afford the title compound as an off- white solid (35 mg, 39%).
  • Gcase activation values for tested compounds are provided in Tables 3 and 4 below, along with cLogP, PSA, and compound solubility in water.
  • the symbol “+” indicates less than 30% Gcase activation; the symbol “++” indicates Gcase activation in the range of 30% up to 60%; and the symbol “+++”indicates Gcase activation greater than 60%.
  • the symbol "*" indicates less than 10% Gcase activation; the symbol indicates Gcase activation in the range of 10% up to 20%; and the symbol "***”indicates greater than 20% Gcase activation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PCT/US2015/059541 2014-11-06 2015-11-06 Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders WO2016073895A1 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
MX2017005940A MX2017005940A (es) 2014-11-06 2015-11-06 Pyrazolo [1, 5-a] pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos.
FIEP15857508.4T FI3215511T3 (fi) 2014-11-06 2015-11-06 Substituoituja pyratsolo(1,5-a)pyrimidiinejä ja niiden käyttö lääketieteellisten häiriöiden hoitamisessa
DK15857508.4T DK3215511T3 (da) 2014-11-06 2015-11-06 Substituerede pyrazolo(1,5-a)pyrimidiner og deres anvendelse i behandlingen af medicinske lidelser
AU2015342887A AU2015342887B2 (en) 2014-11-06 2015-11-06 Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
EA201790995A EA201790995A1 (ru) 2014-11-06 2015-11-06 ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ
CA2966583A CA2966583A1 (en) 2014-11-06 2015-11-06 Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
US15/523,769 US10570135B2 (en) 2014-11-06 2015-11-06 Substituted pyrazolo[1,5-A]pyrimidines and their use in the treatment of medical disorders
CN201580068129.9A CN107001379B (zh) 2014-11-06 2015-11-06 取代的吡唑并[1,5-a]嘧啶以及它们在治疗医学障碍中的用途
IL252053A IL252053B2 (en) 2014-11-06 2015-11-06 Converted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders
NZ731897A NZ731897B2 (en) 2015-11-06 Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
KR1020177015300A KR102662215B1 (ko) 2014-11-06 2015-11-06 치환된 피라졸로(1,5-a)피리미딘 및 의학적 장애의 치료에서의 그의 용도
EP15857508.4A EP3215511B1 (en) 2014-11-06 2015-11-06 Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
JP2017544549A JP6734860B2 (ja) 2014-11-06 2015-11-06 置換ピラゾロ[1,5−a]ピリミジンおよび医療疾患の治療におけるその使用
BR112017009276-0A BR112017009276B1 (pt) 2014-11-06 2015-11-06 Pirazolo[1,5-a]pirimidinas substituídas, composição farmacêutica e seus usos
CN202211277924.7A CN115925711A (zh) 2014-11-06 2015-11-06 取代的吡唑并[1,5-a]嘧啶以及它们在治疗医学障碍中的用途
US15/440,107 US9732089B2 (en) 2014-11-06 2017-02-23 Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders
US16/733,598 US11091492B2 (en) 2014-11-06 2020-01-03 Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders
US17/369,507 US11932645B2 (en) 2014-11-06 2021-07-07 Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462076062P 2014-11-06 2014-11-06
US62/076,062 2014-11-06

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US15/523,769 A-371-Of-International US10570135B2 (en) 2014-11-06 2015-11-06 Substituted pyrazolo[1,5-A]pyrimidines and their use in the treatment of medical disorders
US15/440,107 Continuation US9732089B2 (en) 2014-11-06 2017-02-23 Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders
US16/733,598 Continuation US11091492B2 (en) 2014-11-06 2020-01-03 Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders

Publications (1)

Publication Number Publication Date
WO2016073895A1 true WO2016073895A1 (en) 2016-05-12

Family

ID=55909884

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/059541 WO2016073895A1 (en) 2014-11-06 2015-11-06 Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders

Country Status (14)

Country Link
US (4) US10570135B2 (US07794700-20100914-C00152.png)
EP (1) EP3215511B1 (US07794700-20100914-C00152.png)
JP (2) JP6734860B2 (US07794700-20100914-C00152.png)
KR (1) KR102662215B1 (US07794700-20100914-C00152.png)
CN (2) CN115925711A (US07794700-20100914-C00152.png)
AU (1) AU2015342887B2 (US07794700-20100914-C00152.png)
CA (1) CA2966583A1 (US07794700-20100914-C00152.png)
DK (1) DK3215511T3 (US07794700-20100914-C00152.png)
EA (1) EA201790995A1 (US07794700-20100914-C00152.png)
FI (1) FI3215511T3 (US07794700-20100914-C00152.png)
IL (1) IL252053B2 (US07794700-20100914-C00152.png)
MX (1) MX2017005940A (US07794700-20100914-C00152.png)
PT (1) PT3215511T (US07794700-20100914-C00152.png)
WO (1) WO2016073895A1 (US07794700-20100914-C00152.png)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017108723A3 (en) * 2015-12-22 2017-07-27 F. Hoffmann-La Roche Ag PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
WO2017161137A1 (en) * 2016-03-16 2017-09-21 Lysosomal Therapeutics Inc. Methods and compositions for treating a neurodegenerative disorder in a sphingotyped subject
WO2017176962A1 (en) * 2016-04-06 2017-10-12 Lysosomal Therapeutics, Inc. Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
US9840510B1 (en) 2016-04-06 2017-12-12 Lysosomal Therapeutics Inc. Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
US9868742B2 (en) 2016-05-05 2018-01-16 Lysosomal Therapeutics Inc. Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b] pyridazines, related compounds, and their use in the treatment of medical disorders
US9920061B2 (en) 2016-04-06 2018-03-20 Lysosomal Therapeutics Inc. Imidazo[1,5-A]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
EP3215510A4 (en) * 2014-11-06 2018-04-11 Lysosomal Therapeutics Inc. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
US9974789B2 (en) * 2010-12-08 2018-05-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Substituted pyrazolopyrimidines as glucocerebrosidase activators
WO2018124001A1 (ja) 2016-12-27 2018-07-05 国立研究開発法人理化学研究所 Bmpシグナル阻害化合物
US10307426B2 (en) 2017-05-22 2019-06-04 Genentech, Inc. Therapeutic compounds and compositions, and methods of use thereof
WO2019126776A1 (en) * 2017-12-21 2019-06-27 Lysosomal Therapeutics Inc. Crystalline substituted cyclohexyl pyrazolo[1,5-a]pyrimidinyl carboxamide compound and therapeutic uses thereof
WO2019151269A1 (ja) 2018-01-31 2019-08-08 武田薬品工業株式会社 複素環化合物
US10570135B2 (en) 2014-11-06 2020-02-25 Lysosomal Therapeutics Inc. Substituted pyrazolo[1,5-A]pyrimidines and their use in the treatment of medical disorders
CN111217816A (zh) * 2018-11-27 2020-06-02 中国科学院上海药物研究所 一类flt3激酶抑制剂及其制备和应用
US10751341B2 (en) 2014-11-06 2020-08-25 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
US20210230156A1 (en) * 2018-06-06 2021-07-29 Donatella Boschi NOVEL HUMAN DIHYDROOROTATE DEHYDROGENASE (hDHODH) INHIBITORS AND THEIR USE IN TARGETING ONCOLOGICAL DISEASES SENSITIVE TO PYRIMIDINE STARVATION
US11174242B2 (en) 2016-12-29 2021-11-16 Minoryx Therapeutics S.L. Heteroaryl compounds and their use
US11345698B2 (en) 2016-05-05 2022-05-31 Bial—R&D Investments, S.A. Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders
US11434250B2 (en) 2016-11-02 2022-09-06 Genentech, Inc. Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators
WO2024038132A1 (en) * 2022-08-17 2024-02-22 Mironid Limited Compounds and their use as pde4 activators

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113271940A (zh) * 2018-10-15 2021-08-17 林伯士拉克许米公司 Tyk2抑制剂和其用途

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005058837A1 (en) * 2003-12-17 2005-06-30 Glaxo Group Limited Benzazepine derivatives as histamine h3 antagonists
WO2007108750A1 (en) * 2006-03-22 2007-09-27 Astrazeneca Ab Pyridopyrimidine derivatives and their use as pde4 inhibitors
WO2010051549A1 (en) * 2008-10-31 2010-05-06 Genentech, Inc. Pyrazolopyrimidine jak inhibitor compounds and methods
WO2012007375A1 (en) * 2010-07-13 2012-01-19 F. Hoffmann-La Roche Ag Pyrazolo [1, 5a] pyrimidine and thieno [3, 2b] pyrimidine derivatives as irak4 modulators
WO2012078855A1 (en) 2010-12-08 2012-06-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Substituted pyrazolopyrimidines as glucocerebrosidase activators
WO2012129258A1 (en) * 2011-03-22 2012-09-27 Merck Sharp & Dohme Corp. Amidopyrazole inhibitors of interleukin receptor-associated kinases
WO2013134079A1 (en) * 2012-03-05 2013-09-12 Amgen Inc. Oxazolidinone compounds and derivatives thereof
WO2014025651A1 (en) * 2012-08-06 2014-02-13 Amgen Inc. Chroman derivatives as trpm8 inhibitors
WO2014089379A1 (en) * 2012-12-07 2014-06-12 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4838925A (en) 1986-04-25 1989-06-13 E. I. Du Pont De Nemours And Company Heterocyclic acyl sulfonamides
JP3763997B2 (ja) 1999-05-13 2006-04-05 富士写真フイルム株式会社 感熱記録材料
JP4331823B2 (ja) 1999-05-21 2009-09-16 富士フイルム株式会社 ピロロ[1,2−a]−1,3,5−トリアジン−4−オン系化合物
WO2001051919A2 (en) 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
JP4070966B2 (ja) 2001-06-28 2008-04-02 株式会社カネボウ化粧品 新規ガラクトシルセラミド類縁体及び用途
JP2005526003A (ja) 2001-10-22 2005-09-02 ファイザー株式会社 5−ht4受容体調節剤としてのイミダゾピリジン化合物
CN1281606C (zh) 2002-03-01 2006-10-25 安斯泰来制药有限公司 含氮杂环化合物
EP1543004A1 (en) 2002-09-20 2005-06-22 Pfizer Inc. N-substituted piperidinyl-imidazopyridine compounds as 5-ht4 receptor modulators
DOP2003000703A (es) 2002-09-20 2004-03-31 Pfizer Compuestos de imidazopiradina como agonistas del receptor 5-ht4
US7550470B2 (en) 2002-12-11 2009-06-23 Merck & Co. Inc. Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
JP2004277337A (ja) 2003-03-14 2004-10-07 Sumitomo Pharmaceut Co Ltd ピラゾロ[1,5−a]ピリミジン誘導体
WO2004094418A1 (en) 2003-04-21 2004-11-04 Pfizer Inc. Imidazopyridine compounds having 5-ht4 receptor agonistic activity and 5-ht3 receptor antagonistic activity
WO2005046611A2 (en) 2003-11-12 2005-05-26 Amicus Therapeutics Inc. Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
AU2005212096B2 (en) 2004-02-18 2010-12-16 Msd K.K. Nitrogenous fused heteroaromatic ring derivative
DE602005007215D1 (de) 2004-05-14 2008-07-10 Cleveland Clinic Foundation Kleinmolekülige hemmer für mrp1 und andere multiarzneimitteltransporter
SI1761541T1 (sl) 2004-06-21 2008-06-30 Hoffmann La Roche Derivati pirazolo-pirimidina
ATE390424T1 (de) 2004-08-02 2008-04-15 Sanol Arznei Schwarz Gmbh Carboxamide des indolizins und seiner aza- und diazaderivate
DE102004049363A1 (de) 2004-10-08 2006-04-13 Henkel Kgaa Mittel zum Färben von keratinhaltigen Fasern
JP5094412B2 (ja) 2005-01-19 2012-12-12 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病治療用又は予防用のジペプチジルペプチダーゼ−iv阻害剤としての二環系ピリミジン
EP1851225B1 (en) 2005-02-11 2011-06-15 F. Hoffmann-La Roche AG Pyrazolo-pyrimidine derivatives as mglur2 antagonists
DE102005007534A1 (de) 2005-02-17 2006-08-31 Bayer Cropscience Ag Pyrazolopyrimidine
CA2605351A1 (en) 2005-04-21 2006-11-02 Dainippon Sumitomo Pharma Co., Ltd. N-substituted phenylacetamide derivative and pharmaceutical composition comprising the same
WO2006118256A1 (ja) 2005-04-28 2006-11-09 Kyowa Hakko Kogyo Co., Ltd. 2-アミノキナゾリン誘導体
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2007044407A2 (en) 2005-10-06 2007-04-19 Schering Corporation Pyrazolo (1 , 5a) pyrimidines as protein kinase inhibitors
AU2006304875B2 (en) 2005-10-21 2013-01-17 Exelixis, Inc. Pyrazolo-pyrimidines as casein kinase II (CK2) modulators
EP1963316A2 (en) 2005-12-08 2008-09-03 Novartis AG Pyrazolo[1,5-a]pyridine-3-carboxylic acids as ephb and vegfr2 kinase inhibitors
WO2007150064A2 (en) 2006-06-23 2007-12-27 Amicus Therapeutics, Inc. METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS BY ENHANCING THE ACTIVITY OF β-GLUCOCEREBROSIDASE
AR061793A1 (es) 2006-07-05 2008-09-24 Mitsubishi Tanabe Pharma Corp Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica
US7553846B2 (en) 2006-08-07 2009-06-30 Albany Molecular Research, Inc. 2-alkylbenzoxazole carboxamides as 5-HT3 modulators
AU2007321924A1 (en) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors
AU2007321922A1 (en) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic matrix metalloprotease inhibitors
EP2137187A1 (en) 2007-03-28 2009-12-30 Inovacia AB Pyrazolo [1,5-a]pyrimidines as inhibitors of stearoyl-coa desaturase
AR067326A1 (es) 2007-05-11 2009-10-07 Novartis Ag Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido
WO2008157575A1 (en) 2007-06-21 2008-12-24 Irm Llc Protein kinase inhibitors and methods for using thereof
WO2009060835A1 (ja) 2007-11-05 2009-05-14 Kyoto University 新規ユビキリン結合性小分子
US20110046127A1 (en) 2007-11-08 2011-02-24 Paolo Pevarello Imidazopyridazines for Use as Protein Kinase Inhibitors
CA2706946A1 (en) 2007-11-28 2009-06-04 Schering Corporation 2-fluoropyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
JP5394404B2 (ja) 2008-02-06 2014-01-22 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ阻害剤として有用な置換イミダゾピリダジン類
EP2269990A4 (en) 2008-03-25 2012-04-18 Takeda Pharmaceutical HETEROCYCLIC COMPOUND
JP5425891B2 (ja) 2008-05-01 2014-02-26 サートリス ファーマシューティカルズ, インコーポレイテッド サーチュイン調節薬としてのキノリンおよび関連する類似体
EA201100613A1 (ru) 2008-10-14 2011-12-30 Астразенека Аб Конденсированные, спироциклические гетероароматические соединения для лечения бактериальных инфекций
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
SG178454A1 (en) 2009-08-17 2012-03-29 Intellikine Inc Heterocyclic compounds and uses thereof
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
TW201217312A (en) * 2010-09-22 2012-05-01 Gruenenthal Gmbh Substituted benzamide compounds
WO2012075393A2 (en) 2010-12-02 2012-06-07 President And Fellows Of Harvard College Activators of proteasomal degradation and uses thereof
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
AU2012272815B2 (en) 2011-06-22 2017-09-07 The General Hospital Corporation Treatment of proteinopathies
SI2746265T1 (sl) 2011-08-18 2016-03-31 Nippon Shinyaku Co., Ltd. Heterociklični derivat kot zaviralec mikrosomske prostaglandin-e sintaze (mpges)
AU2012300844B2 (en) 2011-09-02 2017-03-30 Bayer Intellectual Property Gmbh Substituted annellated pyrimidine and the use thereof
US8961959B2 (en) 2011-10-17 2015-02-24 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
CA2852936A1 (en) 2011-10-20 2013-04-25 Glaxosmithkline Llc Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
AU2012355624A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
SG11201405563VA (en) 2012-03-09 2014-10-30 Lexicon Pharmaceuticals Inc Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
HUE036040T2 (hu) 2012-03-09 2018-06-28 Lexicon Pharmaceuticals Inc Adaptor-asszociált kináz 1 gátlása fájdalom kezelésére
JP2015512913A (ja) 2012-03-28 2015-04-30 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ グルコセレブロシダーゼ活性剤として有用なサリチル酸誘導体
KR20150020228A (ko) 2012-05-31 2015-02-25 에프. 호프만-라 로슈 아게 아미노퀴나졸린 및 피리도피리미딘 유도체
EP2865671B1 (en) 2012-06-22 2017-11-01 Sumitomo Chemical Company, Ltd Fused heterocyclic compound
US20150216168A1 (en) 2012-09-05 2015-08-06 Bayer Cropscience Ag Use of substituted 2-amidobenzimidazoles, 2-amidobenzoxazoles and 2-amidobenzothiazoles or salts thereof as active substances against abiotic plant stress
AU2013344716B2 (en) 2012-11-16 2018-03-01 University Health Network Pyrazolopyrimidine compounds
US9938258B2 (en) 2012-11-29 2018-04-10 Karyopharm Therapeutics Inc. Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
KR20140086002A (ko) 2012-12-28 2014-07-08 한미약품 주식회사 Fms 키나아제 저해 활성을 갖는 피리다진 접합고리 유도체
WO2014141129A2 (en) 2013-03-14 2014-09-18 Grueneberg Dorre A Novel methods, compounds, and compositions for inhibition of ros
EP2970266B1 (en) 2013-03-15 2018-01-31 Epizyme, Inc. 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof
EP3026051A4 (en) 2013-07-24 2017-03-08 Takeda Pharmaceutical Company Limited Heterocyclic compound
US20160199372A1 (en) 2013-08-20 2016-07-14 Bristol-Myers Squibb Company Imidazopyridazine kinase inhibitors useful to treating a disease or disorder mediated by aak1, such as alzheimer's disease, bipolar disorder, pain, schizophrenia
CR20160135A (es) 2013-08-23 2016-08-05 Incyte Corp Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de cinasas pim
AR097543A1 (es) 2013-09-06 2016-03-23 Lexicon Pharmaceuticals Inc COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
TW201542550A (zh) 2013-09-06 2015-11-16 Lexicon Pharmaceuticals Inc 吡唑并[1,5-a]嘧啶基化合物、包含彼之組合物以及使用彼之方法
WO2015073267A1 (en) 2013-11-15 2015-05-21 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
DK3461812T3 (da) 2014-03-27 2021-12-20 Acad Medisch Ct N-(5-(biphen-4-ylmethyloxy)pentyl)-substituerede iminosukre som inhibitorer af glucosylceramidsyntase
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
ES2958391T3 (es) 2014-11-06 2024-02-08 Bial R&D Invest S A Imidazo[1,5-a]pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos
PT3215511T (pt) 2014-11-06 2024-05-22 Bial R&D Invest S A Pirazolo(1,5-a)pirimidinas substituídas e a sua utilização no tratamento de distúrbios médicos
US20180185368A1 (en) 2014-11-06 2018-07-05 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
JP2018525345A (ja) 2015-07-01 2018-09-06 ノースウェスタン ユニバーシティ 置換キナゾリン化合物及びグルコセレブロシダーゼ活性の調節のためのその使用
EP3317282B1 (en) 2015-07-01 2020-12-09 Northwestern University Substituted 4-methyl-pyrrolo[1.2-a]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity
EP3344632A4 (en) 2015-09-04 2019-03-20 Lysosomal Therapeutics Inc. Heterocyclic pyrimidine compounds and their use in the treatment of medical disorders
HRP20220599T1 (hr) 2015-11-06 2022-06-24 Incyte Corporation Heterociklički spojevi kao inhibitori pi3k-gama
KR20180081584A (ko) 2015-11-18 2018-07-16 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물
JP6936236B2 (ja) 2016-02-18 2021-09-15 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 治療化合物、組成物及びその方法の使用
WO2017176961A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
KR20180133461A (ko) 2016-04-06 2018-12-14 리소소말 테라퓨틱스 인크. 피라졸로[1,5-a]피리미디닐 카르복스아미드 화합물 및 의학적 장애의 치료에서의 그의 용도
EP3440081A4 (en) 2016-04-06 2019-09-18 Lysosomal Therapeutics Inc. PYRROLO [1,2-A] PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
WO2017192841A1 (en) 2016-05-04 2017-11-09 Lysosomal Therapeutics Inc. Methods of treatment and combination therapies using gcase activator heterobicyclic and related compounds
WO2017192929A1 (en) 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED PYRROLO[1,2-α]TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
AU2017261291C1 (en) 2016-05-05 2022-05-26 Bial - R&D Investments, S.A. Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders
EP3452455A4 (en) 2016-05-05 2019-11-13 Lysosomal Therapeutics Inc. SUBSTITUTED IMDAZO [1,2-] PYRIDINES, SUBSTITUTED IMIDAZO [1,2-] PYRAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF ILLNESSES
EP3728265A1 (en) 2017-12-21 2020-10-28 BIAL - BioTech Investments, Inc. Crystalline substituted cyclohexyl pyrazolo[1,5-a]pyrimidinyl carboxamide compound and therapeutic uses thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005058837A1 (en) * 2003-12-17 2005-06-30 Glaxo Group Limited Benzazepine derivatives as histamine h3 antagonists
WO2007108750A1 (en) * 2006-03-22 2007-09-27 Astrazeneca Ab Pyridopyrimidine derivatives and their use as pde4 inhibitors
WO2010051549A1 (en) * 2008-10-31 2010-05-06 Genentech, Inc. Pyrazolopyrimidine jak inhibitor compounds and methods
WO2012007375A1 (en) * 2010-07-13 2012-01-19 F. Hoffmann-La Roche Ag Pyrazolo [1, 5a] pyrimidine and thieno [3, 2b] pyrimidine derivatives as irak4 modulators
WO2012078855A1 (en) 2010-12-08 2012-06-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Substituted pyrazolopyrimidines as glucocerebrosidase activators
WO2012129258A1 (en) * 2011-03-22 2012-09-27 Merck Sharp & Dohme Corp. Amidopyrazole inhibitors of interleukin receptor-associated kinases
WO2013134079A1 (en) * 2012-03-05 2013-09-12 Amgen Inc. Oxazolidinone compounds and derivatives thereof
WO2014025651A1 (en) * 2012-08-06 2014-02-13 Amgen Inc. Chroman derivatives as trpm8 inhibitors
WO2014089379A1 (en) * 2012-12-07 2014-06-12 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Current protocols in immunology", 1991
"Current protocols in molecular biology", 1987
See also references of EP3215511A4
WANG, X. ET AL.: "Discovery of novel pyrazolo[1,5-a]pyrimidines as potent pan-rim inhibitors by structure- and property-based drug design", JOURNAL OF MEDICINAL CHEMISTRY, vol. 23, 2013, pages 3149 - 3153, XP028535190, DOI: doi:10.1016/j.bmcl.2013.04.020 *

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9974789B2 (en) * 2010-12-08 2018-05-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Substituted pyrazolopyrimidines as glucocerebrosidase activators
US10925874B2 (en) 2010-12-08 2021-02-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Substituted pyrazolopyrimidines as glucocerebrosidase activators
EP3215510A4 (en) * 2014-11-06 2018-04-11 Lysosomal Therapeutics Inc. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
US11400095B2 (en) 2014-11-06 2022-08-02 Bial—R&D Investments, S.A. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
US11351173B2 (en) 2014-11-06 2022-06-07 Bial—R&D Investments, S.A. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
US11091492B2 (en) 2014-11-06 2021-08-17 Bial—R&D Investments, S.A. Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders
US10751341B2 (en) 2014-11-06 2020-08-25 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
US11932645B2 (en) 2014-11-06 2024-03-19 Bial—R & D Investments, S.A. Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders
US10786508B2 (en) 2014-11-06 2020-09-29 Lysosomal Therapeutics Inc. Substituted imidazo[1,5-A]-pyrimidines and their use in the treatment of medical disorders
US10570135B2 (en) 2014-11-06 2020-02-25 Lysosomal Therapeutics Inc. Substituted pyrazolo[1,5-A]pyrimidines and their use in the treatment of medical disorders
US10988478B1 (en) 2015-12-22 2021-04-27 Genentech, Inc. Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators
WO2017108723A3 (en) * 2015-12-22 2017-07-27 F. Hoffmann-La Roche Ag PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
WO2017161137A1 (en) * 2016-03-16 2017-09-21 Lysosomal Therapeutics Inc. Methods and compositions for treating a neurodegenerative disorder in a sphingotyped subject
US10934298B2 (en) 2016-04-06 2021-03-02 BIAL—BioTech Investments, Inc. Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders
US9920061B2 (en) 2016-04-06 2018-03-20 Lysosomal Therapeutics Inc. Imidazo[1,5-A]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
US10787454B2 (en) 2016-04-06 2020-09-29 BIAL—BioTech Investments, Inc. Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
WO2017176962A1 (en) * 2016-04-06 2017-10-12 Lysosomal Therapeutics, Inc. Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
US11192892B2 (en) 2016-04-06 2021-12-07 Bial—R&D Investments, S.A. Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders
US11453675B2 (en) 2016-04-06 2022-09-27 Bial—R&D Investments, S.A. Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
US9840510B1 (en) 2016-04-06 2017-12-12 Lysosomal Therapeutics Inc. Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
US11124516B2 (en) 2016-04-06 2021-09-21 BIAL-BioTech Investments, Inc. Pyrrolo[1,2-A]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
US11168087B2 (en) 2016-05-05 2021-11-09 Bial—R&D Investments, S.A. Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders
US9868742B2 (en) 2016-05-05 2018-01-16 Lysosomal Therapeutics Inc. Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b] pyridazines, related compounds, and their use in the treatment of medical disorders
US11878979B2 (en) 2016-05-05 2024-01-23 Bial—R&D Investments, S.A. Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders
US11345698B2 (en) 2016-05-05 2022-05-31 Bial—R&D Investments, S.A. Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders
US11434250B2 (en) 2016-11-02 2022-09-06 Genentech, Inc. Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators
WO2018124001A1 (ja) 2016-12-27 2018-07-05 国立研究開発法人理化学研究所 Bmpシグナル阻害化合物
US11174242B2 (en) 2016-12-29 2021-11-16 Minoryx Therapeutics S.L. Heteroaryl compounds and their use
US11739072B2 (en) 2016-12-29 2023-08-29 Minoryx Therapeutics S.L. Heteroaryl compounds and their use
US10307426B2 (en) 2017-05-22 2019-06-04 Genentech, Inc. Therapeutic compounds and compositions, and methods of use thereof
WO2019126776A1 (en) * 2017-12-21 2019-06-27 Lysosomal Therapeutics Inc. Crystalline substituted cyclohexyl pyrazolo[1,5-a]pyrimidinyl carboxamide compound and therapeutic uses thereof
US11459325B2 (en) 2018-01-31 2022-10-04 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2019151269A1 (ja) 2018-01-31 2019-08-08 武田薬品工業株式会社 複素環化合物
US20210230156A1 (en) * 2018-06-06 2021-07-29 Donatella Boschi NOVEL HUMAN DIHYDROOROTATE DEHYDROGENASE (hDHODH) INHIBITORS AND THEIR USE IN TARGETING ONCOLOGICAL DISEASES SENSITIVE TO PYRIMIDINE STARVATION
CN111217816A (zh) * 2018-11-27 2020-06-02 中国科学院上海药物研究所 一类flt3激酶抑制剂及其制备和应用
CN111217816B (zh) * 2018-11-27 2022-08-16 中国科学院上海药物研究所 一类flt3激酶抑制剂及其制备和应用
WO2024038132A1 (en) * 2022-08-17 2024-02-22 Mironid Limited Compounds and their use as pde4 activators

Also Published As

Publication number Publication date
AU2015342887A1 (en) 2017-06-15
IL252053A0 (en) 2017-07-31
IL252053B2 (en) 2024-04-01
MX2017005940A (es) 2018-01-11
US9732089B2 (en) 2017-08-15
US11932645B2 (en) 2024-03-19
KR20170082577A (ko) 2017-07-14
KR102662215B1 (ko) 2024-05-02
CN107001379B (zh) 2022-11-01
PT3215511T (pt) 2024-05-22
US10570135B2 (en) 2020-02-25
FI3215511T3 (fi) 2024-05-16
US20170334916A1 (en) 2017-11-23
JP6734860B2 (ja) 2020-08-05
CN115925711A (zh) 2023-04-07
EP3215511A1 (en) 2017-09-13
US20170183354A1 (en) 2017-06-29
EA201790995A1 (ru) 2017-10-31
DK3215511T3 (da) 2024-05-13
CN107001379A (zh) 2017-08-01
US11091492B2 (en) 2021-08-17
JP2020183410A (ja) 2020-11-12
IL252053B1 (en) 2023-12-01
CA2966583A1 (en) 2016-05-12
US20220169652A1 (en) 2022-06-02
EP3215511B1 (en) 2024-04-17
AU2015342887B2 (en) 2020-09-10
BR112017009276A2 (pt) 2017-12-19
US20200385390A1 (en) 2020-12-10
BR112017009276A8 (pt) 2023-03-14
JP2017533968A (ja) 2017-11-16
EP3215511A4 (en) 2018-02-28
NZ731897A (en) 2023-11-24

Similar Documents

Publication Publication Date Title
AU2015342887B2 (en) Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
WO2017192841A1 (en) Methods of treatment and combination therapies using gcase activator heterobicyclic and related compounds
AU2015342883B2 (en) Substituted pyrrolo(1,2-a)pyrimidines and their use in the treatment of medical disorders
CA2898650C (en) Quinoline and quinoxaline amides as modulators of sodium channels
JP6337109B2 (ja) ナトリウムチャネルの調節剤としてのスルホンアミド
JP2019055974A (ja) ナトリウムチャネルの調節剤として有用なピリドンアミドのプロドラッグ
EP3215510B1 (en) Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
CA3020310A1 (en) Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
WO2017040877A1 (en) Heterobicyclic pyrimidinone compounds and their use in the treatment of medical disorders
EP3452455A1 (en) Substituted imdazo[1,2- ]pyridines, substituted imidazo[1,2- ]pyrazines, related compounds, and their use in the treatment of medical disorders
EP3452480A1 (en) Substituted pyrrolo[1,2- ]triazines and related compounds and their use in the treatment of medical disorders
WO2017040879A1 (en) Thiazolo(3,2-a) pyrimidinone and other heterobicyclic pyrimidinone compounds for use in medical therapy
BR112017009276B1 (pt) Pirazolo[1,5-a]pirimidinas substituídas, composição farmacêutica e seus usos

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15857508

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2966583

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 252053

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2017544549

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2017/005940

Country of ref document: MX

REEP Request for entry into the european phase

Ref document number: 2015857508

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017009276

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20177015300

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201790995

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2015342887

Country of ref document: AU

Date of ref document: 20151106

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112017009276

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20170503